0000856984-14-000007.txt : 20141114 0000856984-14-000007.hdr.sgml : 20141114 20141114144027 ACCESSION NUMBER: 0000856984-14-000007 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141114 DATE AS OF CHANGE: 20141114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIOGENETIC SCIENCES INC CENTRAL INDEX KEY: 0000856984 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 112655906 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19041 FILM NUMBER: 141223096 BUSINESS ADDRESS: STREET 1: 79 EAST PUTNAM AVE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 2032976100 MAIL ADDRESS: STREET 1: 79 EAST PUTNAM AVE CITY: GREENWICH STATE: CT ZIP: 06830 10-Q 1 maba09302014.htm FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2014 maba

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 10-Q
________________________________

ý                                  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2014

 

or

 

¨                                  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

For the transition period from    to

 

Commission file number 0-19041

 

AMERICAN BIOGENETIC SCIENCES, INC.
(Exact Name Of Registrant As Specified In Its Charter)

Delaware 11-2655906
(State of Incorporation) (I.R.S. Employer Identification No.)
       
79 East Putnam Ave, Greenwich, CT 06830
(Address of Principal Executive Offices) (ZIP Code)

Registrant's Telephone Number, Including Area Code: (212) 400-7198

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No ¨

On November 14, 2014, the Registrant had 1,088,740 shares of common stock outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer ¨ Accelerated filer ¨ Non-Accelerated filer ¨ Smaller reporting company x

 

TABLE OF CONTENTS

Item
 Description
 Page

PART I - FINANCIAL INFORMATION
 
ITEM 1.    FINANCIAL STATEMENTS. 3
ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION. 8
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 9
ITEM 4.    CONTROLS AND PROCEDURES. 10
   

PART II - OTHER INFORMATION
   
ITEM 1.    LEGAL PROCEEDINGS. 10
ITEM 1A.    RISK FACTORS. 10
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. 10
ITEM 3.    DEFAULT UPON SENIOR SECURITIES. 10
ITEM 4.    MINE SAFETY DISCLOSURE. 10
ITEM 5.    OTHER INFORMATION. 10
ITEM 6.    EXHIBITS. 10

 

 

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents

    Balance Sheets - September 30, 2014 (Unaudited) and December 31, 2013 3
    Statements of Operations - Three and Nine Months Ended September 30, 2014 and 2013 (Unaudited) 4
    Statements of Cash Flows - Nine Months Ended September 30, 2014 and 2013 (Unaudited) 5
   Notes to Unaudited Interim Financial Statements 6

 

American Biogenetic Sciences, Inc.
Balance Sheets
Back to Table of Contents
 
  September 30, 2014 December 31, 2013
  (Unaudited) (Audited)

ASSETS
 
    Total Assets $ 0 $ 0
 

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
   Accounts payable - trade $ 7,625 $ 2,250
   Accrued interest expenses 47,406 38,760
   Convertible notes, related party   331,681   331,681
   Advances from and accruals due to related party 14,875 0
         Total current liabilities 401,587 372,691
 
         Total liabilities 401,587 372,691
 
Stockholders' Deficit:
 
Preferred stock, 10,000,000 shares authorized, $0.0001 par value;
     none issued and outstanding - -
Common stock, 900,000,000 shares authorized, $0.0001 par value;
     1,088,740 shares issued and outstanding at Sept. 30, 2014 and Dec. 31, 2013 109 109
   Additional paid-in capital 46,191 46,191
   Accumulated deficit (447,887) (418,991)
     Total Stockholders' Deficit (401,587) (372,691)
       Total Liabilities and Stockholders' Deficit $ 0 $ 0
 
See notes to unaudited interim financial statements.

American Biogenetic Sciences, Inc.
Statements of Operations
Back to Table of Contents
  Three Months   Three Months   Nine Months   Nine Months
  Ended   Ended   Ended   Ended
  September 30, 2014   September 30, 2013   September 30, 2014   September 30, 2013
  (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited)
                 
Revenue $ 0 $ 0 $ 0 $ 0
                 
Costs and expenses:                
   General and administrative   5,875   14,750   20,250   46,000
   Interest expense   2,904   2,280   8,646   6,840
Total costs and expenses   8,779   17,030   28,896   52,840
                 
Net loss $ (8,779) $ (17,030) $ (28,896) $ (52,840)
                 
Basic and diluted per shares amounts:                
Basic and diluted net loss $ (0.01) $ (0.02) $ (0.03) $ (0.05)
                 
Weighted average shares outstanding:                
Basic and diluted   1,088,740   1,088,740   1,088,740   1,088,740
 
See notes to unaudited interim financial statements.

American Biogenetic Sciences, Inc.

Statements of Cash Flows
  Back to Table of Contents
    Nine Months   Nine Months
Ended Ended
                  September 30, 2014   September 30, 2013
    (Unaudited)   (Unaudited)
Cash flows from operating activities:        
Net loss $ (28,896)   (52,840)
Adjustment required to reconcile net loss to cash used in operating activities:        
   Fair value of services provided by related parties   0   42,000
   Increase in accounts payable and accrued expenses   14,021   10,840
    Cash flows used in operating activities $ (14,875)   0
         
Cash flows from investing activities:    
     Cash used in investing activities   0   0
  
Cash flows from financing activities:        
   Advances from related parties 14,875 0
     Cash provided by financing activities   14,875   0
 
     Change in cash   0   0
Cash - beginning of period   0   0
Cash - end of period $ 0 $ 0
 

See notes to unaudited interim financial statements.

AMERICAN BIOGENETIC SCIENCES, INC.
Notes to Unaudited Interim Financial Statements
September 30, 2014
Back to Table of Contents

Note 1. The Company

American Biogenetic Sciences, Inc. (the "Company", “We” or the "Registrant") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court. On August 13, 2010, the Company's sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company's sole executive officer/director.

Note 2. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management's success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.

Note 3. Basis of Presentation

The Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013. The accounting policies are described in the “Notes to the Financial Statements” in the 2013 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.

Fair Value of Financial Instruments: ASC #825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.

Earnings per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of September 30, 2014 or 2013.

Income Taxes: The Company accounts for income taxes in accordance with ASC #740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed "more-likely-than-not" to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions.

Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at September 30, 2014 and 2013. The Company has net operating losses of about $447,887, which begin to expire in 2025.

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

Note 4. Convertible Notes to Related Party

On October 2, 2009, we issued a convertible promissory note in the amount of $76,000 to our sole officer/director. The note bears interest at the rate of 12% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.001 per share. The convertible note was issued in consideration of cash advances made and for services provided to the Company by the sole officer/director, who was also the Company's controlling shareholder. On August 13, 2010, the Company's sole officer/director transferred and assigned his controlling stock position to an unrelated third party but remained as the Company's sole executive officer/director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new controlling shareholder. A written agreement was entered into between the Company and the controlling shareholder on December 31, 2013 to assign the $76,000 convertible promissory note to the controlling shareholder.

As of September 30, 2014 and December 31, 2013, the outstanding note balance was $76,000 and accrued interest expense balance was $45,513 and $38,760, respectively.

On December 31, 2013, we issued a convertible promissory note in the amount of $255,681 to our controlling shareholder. The note bears interest at the rate of 1% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.25 per share. The note was issued in consideration of cash advances made and for services provided to the Company by its former sole officer/director and an entity controlled by our sole officer/director, who was also the Company's previous controlling shareholder.

As of September 30, 2014, the outstanding note balance was $255,681 and accrued interest expense balance was $1,893.

In accordance Accounting Standard Codification ("ASC #815"), "Accounting for Derivative Instruments and Hedging Activities", we evaluated the holder's non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments.

Note 5. Related Party Transactions

An entity controlled by the Company's sole officer/director provided corporate securities compliance services to the Company valued at $4,000 during the three-month period ended September 30, 2014, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

Due Related Parties: Amounts due to related parties consist of advances made by our controlling shareholder for accounting fees and corporate regulatory compliance expenses provided by an entity controlled by the Company's sole officer/director. Such items due totaled $14,875 at September 30, 2014 and $0 at December 31, 2013.

Note 6. Commitments and Contingencies

There are no pending or threatened legal proceedings as of September 30, 2014. The Company has no non-cancellable operating leases.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATIONS Back to Table of Contents

Some of the statements contained in this quarterly report of American Biogenetic Sciences, Inc., a Delaware corporation discuss future expectations, contain projections of our plan of operation or financial condition or state other forward-looking information. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "continue," or the negative of such terms or other similar expressions.

General Background

American Biogenetic Sciences, Inc., a Delaware corporation, is sometimes referred to herein as "we", "us", "our", "Company" and the "Registrant". The Registrant was formed in 1983 for the purpose of researching, developing and marketing cardiovascular and neurobiology products for commercial development and distributing vaccines. The Registrant's products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Registrant commenced selling its products during the last quarter of 1997 but did not generate any sufficient revenues from operations to fund its operating expenses.

On September 19, 2002, the Registrant filed a petition under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of New York. On November 4, 2005, the Bankruptcy Court approved an order authorizing a change in control and provided that the Company, subsequent to the bankruptcy proceeding, is free and clear of all liens, claims and other obligations.

On August 13, 2010, the Registrant's sole officer/director, who was also the principal shareholder, transferred and assigned his controlling stock position to an unrelated third party but remained as the Registrant's sole officer and director. On December 31, 2013, the convertible note to our sole officer/director was formally assigned to our controlling shareholder. See Note 4 to the Notes to Unaudited Interim Financial Statements.

Plan of Operation

We have no present operations or revenues and our current activities are related to seeking new business opportunities, including seeking an acquisition or merger with an operating company. If our management seeks to acquire another business or pursue a new business opportunity, it would have substantial flexibility in identifying and selecting a prospective business. Registrant would not be obligated nor does management intend to seek pre-approval from our shareholders. Under the laws of the State of Delaware, the consent of holders of a majority of the issued and outstanding shares, acting without a shareholders' meeting, can approve an acquisition.

The Registrant is entirely dependent on the judgment of its executive officer/director in connection with pursuing a new business opportunity or a selection process for a target operating company. In evaluating a prospective new business opportunity or an operating company, he would consider, among other factors, the following: (i) costs associated with effecting a transaction; (ii) equity interest in and opportunity to control the prospective candidate; (iii) growth potential of the target business; (iv) experience and skill of management and availability of additional personnel; (v) necessary capital requirements; (vi) the prospective candidate's competitive position; (vii) stage of development of the business opportunity; (viii) the market acceptance of the business, its products or services; (ix) the availability of audited financial statements of the potential business opportunity; and (x) the regulatory environment that may be applicable to any prospective business opportunity.

The foregoing criteria are not intended to be exhaustive and there may be other criteria that management may deem relevant. In connection with an evaluation of a prospective or potential business opportunity, management may be expected to conduct a due diligence review.

Results of Operations during the three-month period ended September 30, 2014 as compared to the three-month period ended September 30, 2013

We have not generated any revenues during the three months ended September 30, 2014 and 2013. We had operating expenses related to general and administrative expenses, being a public company, and interest expense. During the three months ended September 30, 2014, we incurred a net loss of $8,779 due to general and administrative expenses of $5,875 and interest expense of $2,904 compared to a net loss during the three months ended September 30, 2013 of $17,030 mainly due to general and administrative expenses of $14,750 and interest expense of $2,280.

Our general and administrative expenses decreased by $8,875 or 60% during the three months ended September 30, 2014 as compared to the same period in the prior year mainly due to a decrease in officer compensation expenses and office expenses. During the three months ended September 30, 2014, our interest expense was $2,904 as compared to $2,280 in the same period in the prior year and the increase was due to the conversion of advances made to the company into an interest bearing convertible note.

Results of Operations during the nine-month period ended September 30, 2014 as compared to the nine-month period ended September 30, 2013

We have not generated any revenues during the nine months ended September 30, 2014 and 2013. We had operating expenses related to general and administrative expenses, being a public company, and interest expense. During the nine months ended September 30, 2014, we incurred a net loss of $28,896 due to general and administrative expenses of $20,250 and interest expense of $8,646 compared to a net loss during the nine months ended September 30, 2013 of $52,840 mainly due to general and administrative expenses of $46,000 and interest expense of $6,840.

Our general and administrative expenses decreased by $25,750 or 56% during the nine months ended September 30, 2014 as compared to the same period in the prior year mainly due to a decrease in officer compensation expenses and office expenses. During the nine months ended September 30, 2014, our interest expense was $8,646 as compared to $6,840 in the same period in the prior year and the increase was due to the conversion of advances made to the company into an interest bearing convertible note.

Liquidity and Capital Resources

We will use our limited personnel and financial resources in connection with seeking new business opportunities, including seeking an acquisition or merger with an operating company. It may be expected that entering into a new business opportunity or business combination will involve the issuance of a substantial number of restricted shares of common stock. If such additional restricted shares of common stock are issued, our shareholders will experience a dilution in their ownership interest in the Registrant. If a substantial number of restricted shares are issued in connection with a business combination, a change in control may be expected to occur.

On September 30, 2014, we had no assets and had total current liabilities of $401,587 consisting of $7,625 in accounts payable, two convertible notes totaling $331,681, $47,406 in accrued interest and $14,875 in advances from and accruals due to related party.

We financed our operating expenses through advances from our controlling shareholder.

In connection with our plan to seek new business opportunities and/or effecting a business combination, we may determine to seek to raise funds from the sale of restricted stock or debt securities. We have no agreements to issue any debt or equity securities and cannot predict whether equity or debt financing will become available at terms acceptable to us, if at all.

There are no limitations in our articles of incorporation on our ability to borrow funds or raise funds through the issuance of restricted common stock to effect a business combination. Our limited resources may make it difficult to borrow funds or raise capital. Our inability to borrow funds or raise funds through the issuance of restricted common stock required to effect or facilitate a business combination may have a material adverse effect on our financial condition and future prospects, including the ability to complete a business combination. To the extent that debt financing ultimately proves to be available, any borrowing will subject us to various risks traditionally associated with indebtedness, including the risks of interest rate fluctuations and insufficiency of cash flow to pay principal and interest, including debt of an acquired business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents

We have not entered into, and do not expect to enter into, financial instruments for trading or hedging purposes.

ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents

Evaluation of disclosure controls and procedures. As of September 30, 2014, the Company's chief executive officer/chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act. Based upon the evaluation of these controls and procedures, our chief executive officer/chief financial officer concluded that our disclosure controls and procedures were not effective as of the date of filing this quarterly report due to lack of an oversight committee and a lack of segregation of duties. Management will consider the need to add personnel and implement improved review procedures.

Changes in internal controls. During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS Back to Table of Contents

None.

ITEM 1A. RISK FACTORS Back to Table of Contents

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1. Description of Business, subheading Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Contents

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Contents

None.

ITEM 4. MINE SAFETY DISCLOSURE Back to Table of Contents

None.

ITEM 5. OTHER INFORMATION Back to Table of Contents

None.

ITEM 6. EXHIBITS Back to Table of Contents

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.

 Description
31 Certification of CEO/CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 Certification of CEO/CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

/s/ Richard Rubin
Richard Rubin
   CEO
   Dated: November 14, 2014

/s/ Richard Rubin
Richard Rubin
   CFO
   Dated: November 14, 2014

 

 EX-31 2 exh31.htm EXHIBIT 31 Exhibit 31

CERTIFICATIONS

I, Richard Rubin, certify that:

1. I have reviewed this quarterly report of American Biogenetic Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the  issuer as of, and for, the periods presented in this report;

4. The  issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as 4efined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the  issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the  issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the  issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the  issuer's internal control over financial reporting that occurred during the  issuer's most recent fiscal quarter (the  issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the   issuer's internal control over financial reporting; and

5. The  issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the   issuer's auditors and the audit committee of the  issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the  issuer's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether r not material, that involves management or other employees who have a significant role in the  issuer's internal control over financial reporting.

Date: November 14, 2014

/s/ Richard Rubin
CEO and CFO

 EX-32 3 exh32.htm EXHIBIT 32 Exhibit 32

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of American Biogenetic Sciences, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2014 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Richard Rubin, CEO and CFO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard Rubin
CEO and CFO

Dated: November 14, 2014

A signed original of this written statement required by Section 906 has been provided to American Biogenetic Sciences, Inc. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.INS 4 maba-20140930.xml <!--egx--><p><b>Note 1. The Company</b></p> <p>American Biogenetic Sciences, Inc. (the &quot;Company&quot;, &#147;We&#148; or the &quot;Registrant&quot;) was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court. On August 13, 2010, the Company's sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company's sole executive officer/director. </p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 2. Going Concern </b></p> <p>The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management's success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.</p> <!--egx--><p style='margin:0in 0in 0pt'><b>Note 3. Basis of Presentation</b></p> <p>The Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013. The accounting policies are described in the &#147;Notes to the Financial Statements&#148; in the 2013 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.</p> <p><b>Accounting Policies</b></p> <p><i>Use of Estimates:</i> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p> <p style='margin:0in 0in 0pt'><i>Cash and Cash Equivalents:</i> For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.</p> <p style='margin:0in 0in 0pt'><i>Fair Value of Financial Instruments:</i> ASC #825, <em>"Disclosures about Fair Value of Financial Instruments,"</em> requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.</p> <p style='margin:0in 0in 0pt'><i>Earnings per Common Share:</i> Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of September 30, 2014 or 2013.</p> <p style='margin:0in 0in 0pt'><i>Income Taxes:</i> The Company accounts for income taxes in accordance with ASC #740, <em>"Accounting for Income Taxes,"</em> which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p> <p>ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed "more-likely-than-not" to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions. </p> <p>Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at September 30, 2014 and 2013. The Company has net operating losses of about $447,887, which begin to expire in 2025.</p> <p style='margin:0in 0in 0pt'><i>Impact of recently issued accounting standards </i></p> <p>There were no new accounting pronouncements that had a significant impact on the Company&#146;s operating results or financial position. </p> <!--egx--><p style='margin:0in 0in 0pt'><b>Note 4. Convertible Notes to Related Party</b></p> <p>On October 2, 2009, we issued a convertible promissory note in the amount of $76,000 to our sole officer/director. The note bears interest at the rate of 12% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.001 per share. The convertible note was issued in consideration of cash advances made and for services provided to the Company by the sole officer/director, who was also the Company's controlling shareholder. On August 13, 2010, the Company's sole officer/director transferred and assigned his controlling stock position to an unrelated third party but remained as the Company's sole executive officer/director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new controlling shareholder. A written agreement was entered into between the Company and the controlling shareholder on December 31, 2013 to assign the $76,000 convertible promissory note to the controlling shareholder.</p> <p>As of September 30, 2014 and December 31, 2013, the outstanding note balance was $76,000 and accrued interest expense balance was $45,513 and $38,760, respectively. </p> <p>On December 31, 2013, we issued a convertible promissory note in the amount of $255,681 to our controlling shareholder. The note bears interest at the rate of 1% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.25 per share. The note was issued in consideration of cash advances made and for services provided to the Company by its former sole officer/director and an entity controlled by our sole officer/director, who was also the Company's previous controlling shareholder. </p> <p>As of September 30, 2014, the outstanding note balance was $255,681 and accrued interest expense balance was $1,893.</p> <p>In accordance Accounting Standard Codification ("ASC #815"), "<i>Accounting for Derivative Instruments and Hedging Activities</i>", we evaluated the holder's non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments. </p> <!--egx--><p style='margin:0in 0in 0pt'><b>Note 5. Related Party Transactions</b></p> <p>An entity controlled by the Company's sole officer/director provided corporate securities compliance services to the Company valued at $4,000 during the three-month period ended September&nbsp;30, 2014, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.</p> <p><i>Due Related Parties</i>: Amounts due to related parties consist of advances made by our controlling shareholder for accounting fees and corporate regulatory compliance expenses provided by an entity controlled by the Company's sole officer/director. Such items due totaled $14,875 at September 30, 2014 and $0 at December 31, 2013.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 6. Commitments and Contingencies</b></p> <p>There are no pending or threatened legal proceedings as of September 30, 2014. The Company has no non-cancellable operating leases.</p> <!--egx--><p><i>Use of Estimates:</i> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Cash and Cash Equivalents:</i> For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Fair Value of Financial Instruments:</i> ASC #825, <em>&quot;Disclosures about Fair Value of Financial Instruments,&quot;</em> requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Earnings per Common Share:</i> Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of September 30, 2014 or 2013.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Income Taxes:</i> The Company accounts for income taxes in accordance with ASC #740, <em>&quot;Accounting for Income Taxes,&quot;</em> which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p> <p>ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed &quot;more-likely-than-not&quot; to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions. </p> <p>Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at September 30, 2014 and 2013. The Company has net operating losses of about $447,887, which begin to expire in 2025.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Impact of recently issued accounting standards </i></p> <p>There were no new accounting pronouncements that had a significant impact on the Company&#146;s operating results or financial position. </p> 0 0 0 0 7625 2250 47406 38760 331681 331681 14875 0 401587 372691 401587 372691 109 109 46191 46191 -447887 -418991 -401587 -372691 0 0 -28896 -52840 0 0 0 42000 14021 10840 -14875 0 0 0 14875 0 14875 0 0 0 0 0 0 0 0 0 0 0 5875 14750 20250 46000 2904 2280 8646 6840 8779 17030 28896 52840 -8779 -17030 -28896 -52840 -0.01 -0.02 -0.03 -0.05 1088740 1088740 1088740 1088740 10-Q 2014-09-30 false American Biogenetic Sciences Inc 0000856984 --12-31 1088740 54242 Smaller Reporting Company Yes No No 2014 Q3 0000856984 2014-01-01 2014-09-30 0000856984 2014-09-30 0000856984 2013-12-31 0000856984 2013-06-30 0000856984 2014-07-01 2014-09-30 0000856984 2013-07-01 2013-09-30 0000856984 2013-01-01 2013-09-30 0000856984 2012-12-31 0000856984 2013-09-30 iso4217:USD shares iso4217:USD shares pure $0.0001 par value; 10,000,000 shares authorized; none issued $0.0001 par value; 100,000,000 shares authorized; 1,088,740 issued and outstanding at September 30, 2014 and December 31, 2013 EX-101.SCH 5 maba-20140930.xsd 000100 - Disclosure - Note 6. Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Note 2. Going Concern link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 3. Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000050 - Disclosure - Note 1. The Company link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - American Biogenetic Sciences Inc. - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 4. Convertible Notes To Related Party link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 5. Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 3. Basis of Presentation: Use of Estimates, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - American Biogenetic Sciences Inc. - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Note 3. Basis of Presentation: Income Taxes, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 maba-20140930_cal.xml EX-101.DEF 7 maba-20140930_def.xml EX-101.LAB 8 maba-20140930_lab.xml Net loss Interest expenses Preferred stock Total liabilities Entity Voluntary Filers Cash flows used by operating activities Total Assets Cash and Cash Equivalents, Policy Cash flows from operating activities: Document and Entity Information: Policies Note 3. Basis of Presentation Cash flows from financing activities: Net loss {1} Net loss Basic and diluted per share amounts: Document Type Note 4. Convertible Notes To Related Party Notes Basic and diluted Total costs and expenses Accrued interest expenses Amendment Flag Advances from related parties General and administrative Total Stockholders' Deficit LIABILITIES AND STOCKHOLDERS' DEFICIT Entity Current Reporting Status Note 2. Going Concern Change in cash Fair value of services provided by related parties Statements of Operations Stockholders' deficit: Total current liabilities Fair Value of Financial Instruments, Policy Note 6. Commitments and Contingencies Expenses paid by issuance of common stock Weighted average shares outstanding Basic and diluted net loss Costs and expenses: Entity Filer Category Entity Public Float Use of Estimates, Policy Cash used in investing activities (Increase) decrease in current assets: Statements of Cash Flows Advances from and accruals due to related party Balance Sheets Entity Common Stock, Shares Outstanding Cash - end of period Cash - end of period Total current assets Impact of Recently Issued Accounting Standards, Policy Cash generated by financing activities Accounts payable - trade Income Taxes, Policy Revenue Total Liabilities and Stockholders' Deficit Entity Registrant Name Note 1. The Company Increase (decrease) in accounts payable and accrued expenses Adjustments to reconcile net loss to cash used in operating activities: Entity Central Index Key Cash - beginning of period Cash - beginning of period Cash flows from investing activities: Current Liabilities: Earnings Per Common Share, Policy Note 5. Related Party Transactions Additional paid in capital Common stock Convertible note, related party Document Fiscal Year Focus Entity Well-known Seasoned Issuer Document Period End Date ASSETS Accumulated deficit Document Fiscal Period Focus Current Fiscal Year End Date EX-101.PRE 9 maba-20140930_pre.xml EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!`=`G4G0$``(\,```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EUU/PC`4AN]-_`]+;PWK MBHIH&%SX<:DDX@^HZQEKZ-JF+0C_WJY\Q)`)(9+8FS5;>][WV4EV\FXP6M8B M68"Q7,D#"8K#3;QU=+F MJ')./V!LBPIJ:E.E0?J=4IF:.G]KIEC38D:G@+M9UL.%D@ZDZ[A&`PT'3U#2 MN7#)\](_7I,8$!8EC^N#C5>.J-:"%]1Y4KR0;,^ELW%(?64X8RNN[97'0+C5 MH=GYW6!3]^9;8SB#9$R->Z6UQ\!+@;^4F7TJ-4L/B[10JK+D!3!5S&O?@=1J M`Y39"L#5(@UK6E,NM]P'_,-AB\-"S@S2O%\0/I&C&PG'=20<-Y%PW$;"T8N$ MXRX2CGXD'/>1<)`L%I!8)BJ)9:226&8JB66HDEBF*OFOL>I\W`,./P.S'\!@``__\#`%!+`P04``8` M"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^U MC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B M(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[ MRW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@ MH@0!**```0`````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````"\ELUJPS`, M@.^#O4/P?76K:Z`.<;ZS)A)K$(@*3VZ(Q52;>]L\/2Q'YH$VA6VL@$T?P8KNYOUN_ M0*L#'O)UT_L(LQB?B3J$_E%*G]?0:3^Q/1C<*:WK=,#05;+7^4%7(),X3J4[ MSR$V%SFC79$)MRNP_O[88^7_<]NR;')XLOE[!R9<*2$_K3OX&B!@4NTJ")D8 MEKP\[2PG2"SD=1@U9:914Q)G5#D^'%OL[F#F)Z;J<]L@92R86[.@S*B$F48E M),ZH<@+^W?![3TZA/'T5!<&MA#:2&PO=V]R:V)O;VLN>&ULE)1=;]HP%(;O)^T_1+Y?\\%'"P*J MT=&-FPIMM+VTW.2$6$WLR#:C_/L=!Y&=CH"ZJ\1QSN/7K]_CR>U;50:_P5BI MU93%5Q$+0*4ZDVHS98_K^R\W++!.J$R46L&4[<&RV]GG3Y.=-J\O6K\&"%!V MR@KGZG$8VK2`2M@K78/"F5R;2C@^5_1VGT[ZJ&`73/U+#-7X'P41>VW'R`WA3M^1'Q(^(V# MN$[S#%2SO:,C'$^*+Y23;L^7ZN"^U'B$WO4E[BQF@1E+?#'++/;"*>5K!4:F M0O&YU!M0X&3*?Z42`P&6+PDE(93D_R@HH!73(YC&[X^+004MID\P_7_5/&@' M/.9X;OQ.5[50>U(97Y/206=IPK]K;`8L1A<,IK5=-L;6:+UL0D#E-^OV^%Q8 M:;G.^,ZDH4[S__,-?(,UIAL?;?_8'``#__P,`4$L#!!0` M!@`(````(0!*SF?6?@,``+@+```8````>&PO=V]R:W-H965T&ULG)9=C^HV$(;O*_4_1+E?\D%(``%'&U;;'JF5JJKG]-HD!JQ-XL@VR^Z_ M[TP&`C8?Y9R;71*_?OW,C#/V[,M'77GO7&DAF[D?#4+?XTTA2]%LYOZW?UZ? MQKZG#6M*5LF&S_U/KOTOBU]_F>VE>M-;SHT'#HV>^UMCVFD0Z&++:Z8'LN4- MC*REJIF!1[4)=*LX*[M)=17$89@&-1.-3PY3]8B'7*]%P5]DL:MY8\A$\8H9 MX-=;T>JC6UT\8E7:#,`N(-#+F"?!)`"GQ:P4$`&FW5-\/?>?H^DR2OQ@,>L2]%WP MO3[[[>FMW/^F1/F':#AD&^J$%5A)^8;2KR6^@LG!Q>S7K@)_*:_D:[:KS-]R M_SL7FZV!EV<[] M83H89>$P`KFWXMJ\"K3TO6*GC:S_)5%TL"*3^&`R!/K#>#R(QZ-HE/Z_2T!$ M78`OS+#%3,F]![L&UM0MPST83<'Y&!EQ]+'>"A5B1)-G=)G[L-TA"@WU>5^D MPUGP#BDM#I+\4A+9BN51@94`NAX1`C]'O)[T(PF*D02+@&@YO0#O'BUVUKU4 MC))>8I%`@AXG03$4^FSA]&1+;"1)SB2C?N%.L;RGL-#`Y'$T%,]]B+O/21K: M"^Q^?]9X>+.@>*B==8S[A42Q@S5VL$B2T4Z+DG'F5'IY+KB1LLF/,*'889HX M3"2Y7L7K8U8%(]C@C^>H4]M`V2E.ZA0'S;%XETDZ"%QD&PL[[,.EBZ@?GW>) MS-DR^4%S!XM,[F-A`WX5T]#PB#>TI)Y7+&X-VIK#O/HY$7=I"NCC^ MCIT<#\<+I.N#-M(/=7BX#;F;/'-/GX/&K0VUT!N#A$07);I'U%QM^))7E?8* MN<-+4`R?Q==@&0XRZ.F* M;E[T8&3;W5Y6TL"-J?NYA1LRAS,_'(!X+:4Y/N`"_9U[\1\```#__P,`4$L# M!!0`!@`(````(0#$Q79PKP(``"D'```9````>&PO=V]R:W-H965T[%S<4FB[+7A"^')]S[KWV977]J&OR(*U3ILEH/(DHD8TPN6K*C/[\<7=Q M18GSO,EY;1J9T2?IZ/7Z_;O5WMA[5TGI"3`T+J.5]VW*F!.5U-Q-3"L;^%(8 MJ[F'I2V9:ZWD>;=)URR)H@737#4T,*3V'`Y3%$K(6R-V6C8^D%A9W]KKT01K=`L56U\D\=*25:I)_+QEB^K2'OQWC&Q8&[6QS1:R6L M<:;P$Z!CP>AQSDNV9,"T7N4*,L"R$RN+C&[B]&9)V7K5U>>7DGLW>">N,ON/ M5N5?5".AV-`F;,#6F'N$?LXQ!)O9T>Z[K@'?+,EEP7>U_V[VGZ0J*P_=GD-" MF%>:/]U*)Z"@0#-)YL@D3`T&X$FTPI,!!>&/&4U`6.6^RNAT,9E?1M,8X&0K MG;]32$F)V#EO].\`BCM3@:NS=LL]7Z^LV1-H-Z!=R_'PQ"D0'SP%AM[EWTR" M.R39($M&X9R"OH/"/JSC>+YB#U`-\8RY"1AXOF!Z!`,WO26P,;3T=GD.R@A& M92P76KD)@:%,\K;,]']D$`SU'IJ/%CUO4`Z8V0#S4H)1@@`Y/T$$0W.&"<7Q M:^D`.D,:#LI0&MN=X.DY7637?7U&&6[&$N>5D+P6"E$9MTA M'IZ2RS$M9C*=PIT\S8^[QOPA,DID^78B.(8'5^6T$(+'0B%RG,AR3-O=P.B? M+<%=8_X0&2:RC%XE$D93N/]:VE)^D'7MB#`['#L)7-P^VD_$38*E?QV?I9MN M4K+^`TRJEI?R*[>E:ARI90&4T>02,K%AUH6%-RWXAGEE/,RH[K6"7Y*$NQM- M`%P8XP\+$&;]3V[]!P``__\#`%!+`P04``8`"````"$`[A%:OXL"``!>!@`` M&0```'AL+W=OT'XP6-"R0&:N[0OZUD:X]L2IQ#I[C9[=L+H56+%%M92_?(-O9+":*L+%R$="T;?YGS%KA@RK5>YQ`Q\V8F!(J.; M)+U94K9>=?7Y)>%@!^_$5OKPV[/[KFO` M-T-R*/B^=M_UX0O(LG+8[3DFY/-*\^=;L`(+BC319.Z9A*[1`#Z)DGXRL"#\ M*:,3%):YJS(Z743S93Q-$$ZV8-V=])24B+UU6OT.H*0S%;@Z:[?<\?7*Z`/! M=B/:MMP/3Y(BL?):,XISB=HN%?5PGR7+%'K$:X@5S M$S#X_(OI$0S=]);0QM#2^^4Y*GNP5_;E\E9N0F`H,WE?9OH_,AZ,E1F:CQ<] M;U`.F-D`,^\1HP01&0+,>T/I$%SNUI>K]I3!\BHSQ>CTLX MS^'0*#`E?(*ZMD3HO3^K$YSV/MI?(YN)-_PZ/DLWW?7"^@]XO%M>P@,WI6PL MJ:%`RCA:8GU-N"#"PND6?>,AUPX/=O=:X3T../!QA.!":W=&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3 MHD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%= MW_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\ MHYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)< MF+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,? M+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^? M_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T M0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0 M."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]> M)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H M'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U M9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,T MD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT M&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLU MUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^ MI+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF M$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TS MY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@ MG^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZG ML?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]6QE6A\?",%*#/!H^^W@:]]<>/$B\*QWKEMZYH;.M'""U=C_2]/ULU`UY+4#A>V M'X7N6']U$_W[R5>_&R7IJ^]^?G;=5`-$F(SUYS1=W[=:B?/L!G9R&ZW=$%>6 M41S8*0[C52M9QZZ]2*A1X+>,=ONN%=A>J&<(]X$C`Q+8\-$P=I.O;GG M>^DKP]*UP+G_L`JCV)[[H+KMF+:SPV8'>_"!Y\11$BW36\"UHN72<]Q]EL/6 ML`6DR2C[O/[N+?_SR]?ZU7[[16SLQ'"9\C^)8Q^#2VZAF"`>G3;9)3\IGVQ?9SI$#TG\J-82^%EZ,?.A';@9G?, M;-^;QQ[=MK0#SW_-3AMT@@5&?E_@P4UTLI5)N*Z<.;'9Z30@&H).73K#ZQ1` M)9M.GM;)_M#P6!H=CNFR8P\SR/:"Q?NUJ4:IS$S[3/H@<&P.QC> M&2#2-@=,U%49=$&@W^L->IVA8>)_-GFY/(.F;=K357N58Z#(JQP#15YE<^I6 M`YD_[RE87E#<5SD&BKS*,5#DU7[#&;BOW*L<`T5>Y1@H\BI;"6JPKV+93G%? MY1@H\BK'0)%7&YM\YAEXJ-RK'`-%7N48G.U55EVAGIM'\0)5ZVYQO=-&+96= MFXQ\=YFB8$P8:TTFV-G(BXEH<@.)LVZS;[9[IL]XRXK;!H2';@+;Q/L:U?(/N@_ MF)%L6ZTX9\.P$))7ON7238N\D+M/L@5S-?.T9`/$Q"XD)%LTH6.YC"FK(]=" M3D>N@:2.7`M9'=%U#G6NG247T0:/U-XZV+(&[3:KCFK'RV%`COB!B*ELLV_/ MRB8'+%K91M:F.^,AO^SUC:E!'S:+/*!I18M]/2L:'-"RHH6LCF+<'-2X*/$I M/1]@\L;>PNVG:.2I'B.'X_K^9\KE?UL6PP=6+B:C[9)[B(IGG/24D9[1TE[WV7S]M@KD;6^QQ-Q/!SM(R9'DT96-<>Q[,UXF-\ND?X='(@&3[GR#>/R(>=I.UQCGS4]@>="+LH ME8_@DI;?9#S0QH,\J.$"/JA/\6F2`2JX'0,X004#VBB1VP#AJ8(!9L8[!@C0 MD@'HG(B*<_H!)LJ%2,1`*1+R+R42.6:GI2#R@EH>2[^0?T)+2TB_9YF9R[<( M]-+,.#A!X"R1QU*LJA3#N1T]K30!#DZ8P,*HV\R0USF6\Y49A$NZX%!:!&G@ ME$6:BTHNYT)F2>"T1:8-SD.XH*!4I)H"Z"BAP#FBHVC\[?`<%(W`?#0H&H)Y M"L(8?,4^P7M"&"$5<0`?);VBG"=TA!'CBF;@**C*D%PT&*I2),]!58XL76&H M2I$$JA3).$6V^&73;!&56S]%J75\*10.VI7_;WVU758NI':.%4W`VC7/JJ>L M;R@RZ29:"%9Q*^5CRUK4ZPANWSQE<)#Q=88A*S5E17[DP_R8RQ,7MR@BI M)$&+.ZHY4+=0S8'\G7-H/`R;[Z944U0EHEJ9I#)../M:%)CB7:OB=I>_.0']E"06Z6*4?P9##,B&D+E;I1WB!QT*XU<4J_&C" M<1Q63]+V=P?]*,8JS>IE>/%8I1_%6.U*QBJ/5?I1C%52N2ZOTH]`Y>QEXD)= MK-*/8IXP)?,$KV/I1]'V/4G;O\VH8L0;DA&?H92^PS?.1OC!FI2-,I32:V*4 M=R6C/$,I_27&MRD9WQE*Z2G@<1J9N"#C]0RE\%%7M*XI:=VIO=AE73%@#$F3 MX$T%SL;'&R0B>O\$JUKQ>@->(5JCE%%H]NPZ+]H,FY`*(+$_T#`J`_2X7?MV M:*=1_*I1I5K`B4[O2<+]*8H*&XD(!@YE"/V`MW7@12`:[))92(QAJA#JP!1] M030//;:J`X/6&1LQ_J@8J`.#UAF,F%1I_B0#\R%<;PH/B;F4AFX9B(]>^.(N MQ,@1+6R`I`S2)W>3QG81?V*7,B0-\XFVKA488HI@.]'>SAD_8:?:SHA4Q7/) M@)X$RQ#_<9-R9F3/C\NY!7YY)P7RY*78G+KKQ"(/T)+A\11A]:B`>)-1)#'^ M:L;?S5-K$WUO_S..T/ M'QXMXV;0G@YNS*[;NQGVI@\W/7,V?7BPAFVC/?LO3$8O_[G'VV/.>+D.>PD0 M5N,ZYGWBXQ4\<:YL3OYS>6ZL&PO6Q[\OL.]0X'I@&R`I4;)LV6-KH,A6QCL;6['D#(+!?FBR MBV3'S6ZF+Y(UG_(:"^P`>98\2IYD?N=4]85L4I*S&Z\_;)"+U=U5=>I<_N>J M//_3QT5L+FV61VGRHC<:[O:,329I&"6S%[WW%Z>#PY[)BR`)@SA-[(O>M%86V2O^C-BV+Y;&3+S`9A M/K>V6,0[>[N[CW<6093TS"0MD^)%;V]_OV?*)/JQM"?NR6CTM'?T/(^.GA=' M+]-)N;!)82##O$J*J+@VKQ.W/V2;!^_/7YI[#Y_O%$?/=V2)6_;4?),FQ3QG M26C#];?G=CDT^[M]L[<[>K3^\M_+I'ZYO_[R%G*>K7]_?_V!O\([.XOR(@NX MV)M@8=>_NG^\L%DT"1+S593.;&*+:&+.)Q'BL3GWGZPOJ.FZN%YV=QOM#K[= MNN*,DU+A;6A>!D5G,90DH4K@-`YFZ[O= MU;O\=7CP^.EA1PHG99:QW)Q&^80MOK=!MI7$^X/!:&^P/UK?OB(C72S0E/,B MG7SHF_-YD,'#MV6AJHVN;UEV5HYCN'X:IT&QY9/3*+:9.8%KLS3KWNY\$<3R MP3N[3+."D\Q)NE@&2>?+BE!_Y^;[\R(HRGS]]/O?V\XSO\5W:5PF19!=PSB. M[GQV_TVZOIM?^5<;QX,/27H%IVR08_"A>9WGI8-O]]=/O\DR^F(:0S,P7P5Q@*D@;%`GWP82+RT?[X\4!CKGK&ZQ3L5% M6J"5$R^P(,\Y9O,WQQO?'4\4_7*S#*Z#<6RA&5,).Y;$=UF))**DL*AM8>Q' M$#;ORO\D34#R(I*]DK2P?9/9&,4,.2$K.AIW'%X*@W(SS=*%8FL@)V',)BRM M*=*;EZ]>/XZ"<11'1=0ERWUXPP=GF9U:3#W$TV"?ZSR\_\O/O_R\_O!OH_]< M?X1AB8UOW.-O>YW/C\,0F]W"%B.1)SF,HA+^T)5KU:^P,O]TBZ7=9-&500L06O%"N4FGYNW29H'(;ZMI[]_9_W<,?]M1 MZTQ\9R]M4G8L]FN\M3@]B5>"+Z++SY>O;;-I;69IS:]ENF^V_L86) MT[P#0%\%.0Y,5H917`H6$$C<[Y.)UH6/28P""9HR$8$U66Z@(,C M0#Z_9<$JM-]R0=U=`DSH<#1-HP3>WD+3/$AF@(N@9CY?EY?N.3!C0MPDD8U@ M/AX,S,:&@NYG9;^"2?=)3_)HWU<<*#@CU[/B;K]?89!;,D`1RE@R6>8!%,;$G*(.[-?9`/S=L5$I]*U%,=W=S33`D; M0T-^9<9!\B$KE\7DFNP,KZ:4O!^>#XFNZCT'R=BM(0VD%[LO:1).#/\B62?M%;BH)DE[9WM'&E65MZ=`&'!,,T&9$C MO-&C+WGC:.`\DORXQ(RKGAZ10EXI;C$J.63>#D&-@4,U22%3 M,2=46T2S.01D0IA:%KJ`W,%,) M7VI[%)XWIU>@)&E>7L;B5CB@,IR\KXK:&(\SE*A5-_,T>Q>#2+\MR1-M!HFN M_"`N[11BR3(&WY)?I&5,Q"2^*'#Y4IK\@,*HZU$QB6`;`FNZ7>@J+U=8BHJJ MQ%1)=4-LS1PG"3GH!@K^HCR17:ZE$B1F3;EJ/;-PUVPK1TH)A[@.5;?`03[) MHC$+O:+@[]\H&=BW;+U)924<\)]3S-B_B4(!J'(92FP`_P&J2IY]MP-,KAGJ M*)6[#"3Z&?MZA59)#5L$@KEB7Z)S:(-BM<2*&`Q0A/BYE$0D.&:>>?]XDY;V MU4>%*>M6X`&=#:FQD3\`HH"5_;'$26IPW&9D8V4;S'&3X;D;;M3.6I;%/+,. M4XD3K2&#EY*M$VX33C79)$(4VBO&1BAK!,Q.O-]P#J`)JJO#A8&JG2675?WA M@3P4;$QY@YF!SMQLONHMW/T?)+&CL@%[ER?9*=PPWUR$L31.(ODNVFP MD%OKRCUYH(5WZQ[@F=-,'N[H"5JC[X8(ZC/1+CRZ@O*!3\K%V-Z@OJUO)N$S55A*$? M51D=I3&%[&:1.B!-;8;F>%((=E5*1X8(8(81-T;9I,HFRVK^>+U"$>JN!7\N MCC1Y$B31/[S"&)$U=_VB-.A4[&<#1]&J.B:H86HE('I M`^21_E>`S?-R&_.U8/"=%-=DX\8=O$[(7;0-]46)X?C\Q/S;X1X9DT,@@1:/ M+I%`P^^/,$<]TKK:=[B`]@Y,[/H'V"*6,_B7Y:E?"KIE&AD M`R+YA*72"XW;74A%B5!D=R./U&;M1Y]ZU;&)Y!BE2^B%GJIG()V%1O$TLU&\ M4+JOJK10*AN#^FAOZ9X-+'>!@46U+@0%'6Q0R=DJQSH/X:IC>!V&#E^$;X`G M?8V.KGL^MYDG@$2:C<(@P.I"=UFX#4>E-"QYX#90>4V!>&'-1?#QRXOY3UR] MKRJ>.#Q&E$)P(00+S$K.URZ^:(Q!W^__,L9HI5RB6&T>?U&1Q-4\FLR;>((: M3SJC%N7MNXH(I/S0XGDU`,#%L/2282MIX0,)S5>\P/>10U5F5#RFGG7`GK0V0HJLW]"] MP/=***[`4`%2BT+M"JD8B]RPJL1I,1HVS,A=M':Y!/.TWB0%\>(J M'=`'68*$J53Y!,%#*VF/%#[T)$V%A;^RJ[^+?`;Z>4T2^LE*LKQP.57[>+,H M:8+PK95@2VI0W2/BZ(.-HWG*M)=FXU'A:O>LREGMFA?JG>Q'2)-4RWZDX%!5 MME^[7'KE6&X<6E0C-+U%FMF!GG$]8/]D@!QZ_@;U_ALH9PL8`/00)&N.!XL@NM5#DMD(_)`#6:8DR]1N(^E M_4!S`V6"/?(H,0>[?R!AK?F*^"HM=0KG8GPJM"XD9DZHB-62*D\HT0:.L-:L M5:7BIP^P!ET7FBH$%W1`ST40'AK8C1\$#Z2U4=>RX"1=O@.^DM:4%(A1VK0M M5=E:&W=3&]9S"\H_W?X'$NV<"IO6<+SQ-%.634>EXFU%(4P4*_3-4:H[VH6H MAVX2RVFT?_P@C*MX2V=-$1,]U\-K@\9Y=U,:C934%[=[P[Z5!%`1@I$K`1@2 MP&#.B,8E;_<>/7K2/SQ\`@8I8&NCVK%E2>E3U&EO=^]@_;:;T\?7]-!H!K$Y MQ`.04I+4F9O*S0H%\!-(X40,RE""A+[I2=$T3ZF.,ST@!J%)!@E$C MS4I`B@%1ZI6>`M?2\`+X]:?_XL8U"ZJB%!#66$F%7.L7=4W$1T-I/!*?NIFR M-UHHOTC-.S]6=K9IK$R^,AM7HG4WKGR;F+=T9F5ZB'XX2DN#^DK2#)E?XL8N M5G:T@*$+7C!R*4JF`EM%T'M/'NM4%(=*5V%C"UCMSZT?J]G4(W9HFVPG?DKD M.MK[@X:_`;V)!79:1'YH#&;*=TJ"Y@A^`*3>""/P9',%GJ9UEN.`U,N*MM^D M-<4BH6IU7XVQ768!)3JVQ008/-)8UUVAS1FE10<5'-]095[G3+LTM5XMA@75 M_-^"H4.U)'%OTD1>'9&!YC;P>!S:R%`QIU1[$NI'6\OT@MI2C]4:)(%TDW*_ M;P/?G29CA;67%C,'M7^/)KXT%6$VS8G5GIB?3P"I=LVD&9RABLV,@7.''1%6 M0:&HS.;Y!:;"X7#FPB@P8W5*5%1`I8#]TEL"E'"N;L#!2U2@AF.%AJY0CLT5 M]=5"?#+.S@5^LB4P1/+F=7ELBRL9#F@)6A5)?MZRLX2UG::=BD2ITZTJVVWS M9-W@_1VVG-+!L^,M13$EMT./$TD[BU2KJEITPH>*QHU6[[L%=4]/%SPZZ!_0 M/90%]_89I'Q,0@4H2XQ*=AIW^^W@X0;*?CLB[AT<]!\?CH39`HG;6*>NU-WW M9E#\@C!Q[V`=$C\##$K\!60RG;3%0E4W)!DJI'M6\1OC`4.W.J4;,71)4RI* M2W4J&^WV^4H?DKQFB][?1<,K?;F[BH_ZAT^KND@5(FI+"UQL515:R?RY#XL( M-$A!M8T+0#SHN;[&Z*#WL&^ZG8+/U=IH$2J^\245O4O7:&ZU@]2B_VQ#&E,S MZ0"N#'&V^C&?H;UQQ`0C^-#*_P!BYV9QP$R##T@X`SR0U!<-62`@ M]C+2GT7BK@6G6608+"@DHW1Q4.;\6H%HLLL4"2X$ZW$)"])>IOBTGJ[/U`"! MFB;%O9H[?R4KIN1/U!-R\R,-TV@JS@D^&ID"U#(?T4K%ZG:7@KA(PD%)KH?F MO*34\K]T*0H@C$;K8`'V"=EC0B*7^/,SQ+4(:L+G%FG>XR#ONIE;N"CZ8+@: M]IH+&3PD8Y">>,=>M\!%R\,BRX]TN"YU1;0.8V!MEA]21=QM=R.Q,?HE%4J:6+M2RJ+6'@\02-SFM.VBA-TLFY4`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`W#_C0.#=)\&`^\P(ROA_%IY'F7^1I5]`B5%!M4B4&E)(HJF'G&L5*L4T5&6JF2J%/T=`5+BU_CT@37P#3! M#;+9(V12;)`97XU42?R@.UE/GN,9@FPD,*[N?"0POF7KD>!R>K6M"&W+`U7K MU`:0(T7BW:X1^([4C#K0IO MX56>$\-UQU3KIAX$;;OV9T,%M%S=SSVTV!@:#\\!\992T3_(%YR;]M4O```` M__\#`%!+`P04``8`"````"$`1BUDY^H$``#8$@``&````'AL+W=O<*CGP/*X&XL@+F-F),H]K>"WW3G4L>;QMC/+,&0V'$R>/T\)&#_/R$1]B MMTL3OA;)*>=%C4Y*GL4U\*\.Z;%2WO+D$7=Y7+Z>CD^)R(_@8I-F:?W1.+6M M/)E_W1>BC#<9Z'YG7IPHW\W+E?L\34I1B5T]`'<.$KW6/'-F#GA:+;8I*)!A MMTJ^6]K/;!ZQF>VL%DV`?J3\7&G_6]5!G/\HT^VWM.`0;5@GN0(;(5XE].M6 M#H&QK12G.%N0T1*0ZQG*'L#DX4W%'SMU*_&PA8`6DDV?II?$%,:X@ M>]Y6[G#AO,&")RTD0`CLUPXR,A&A0LC5E5[7:N!BXC+3)E(0F5N@J),%2ZC+ MZD\CQ5Z"(6$T:B[A%B`$EJEC/S:9A`K1L5<#/S6)%(*2!R:/DY?@I0VN.F:N M:U(+$.(WZT*6)<0YK]D'3=!O@",-;$0;XO(X80DFA#U"&"%>+V$UU\59#X- MVB3OD>0,6LP-]BU"HV_8]/+7;4P!LC>1S&&^_'RYDSP,FYI>TCT2M:#%0'WK MRKY'>E;88B#`%PQI#>L'_$2W_9B:94O[)$T9T2M@`].^^81+J)25]V MQL?I8Q\UZ).='S#$(/TGS_.G5\6AA>@"3",VG5'5D6YD2I!=\G$)V%,-";0D MRP,'5$`EH:^^M1!=@F'47R(0TAB9$F2_U"3(K^_[S85AES6DD,T0M)C^;[YV M4A>!+GOAD0XWZJ=&_LP>PPT*]5)]N`;L:"J^'UM=#D3%DS4D+PJ:%W!$.K!HS^>/7->[GG(LZRR$G&2Q_HQ?#IW MHWCE$+`Y'`G!GHROY55$S_@S\V'"[YF!E8*9:>_,3-UK.-W/P+W",=[SO^)R MGQ:5E?$=$(3S/.SB$F\F\*46Q^;,NQ$UW"@T_Q[@!HG#T74X`/!.B%J]R#!T M=U*K_P$``/__`P!02P,$%``&``@````A`(R5"#3@`P``0`X``!@```!X;"]W M;W)K/_^/[R9>%[2M,BI9DHV,;_8,K_NOWUE_5%R%=U8DQ[X%"H MC7_2NEP%@4I.+*=J)$I6P#\'(7.JX5(>`U5*1M/JH3P+HC",*>17+.6:&-B609U<"O3KQ45[<\&6*74_EZ+K\D(B_!8L\SKC\J4]_+ MD]6W8R$DW6!LL`G+;KE,,(,.V> M9(>-_T16,9G[P79=)>A?SBZJ]=M3)W'Y3?+T#UXPR#;,DZ;[?UC&$LU2F#G? MPQG9"_&*CWZ#6R$$494`@ZC_KV&>(HP2-&':OZ\A7ZII^TMZ*3O0-$2:0AHP&ZOTXYFI!*8!8HVB*;HF(@,+^/1RCNL)TDC?#1U/]6GCCV>C MZ3P<$Y![>Z;T"T=+WTO.2HO\/R,BM94QB6H3^+[4)F0TB:;SQ2,NX]H%OFL7 M`H;W$0(SG"I3SU33[5J*BP?K%(!527'5DQ487M-B!M$DJB]/D"`T>4*7C0\% M!BE0,%EOVW`=O,%T)+5B9Q3PV2B(K8BO"IQ1@&L(86QMPL\G[`J"8@3!"42R MG;G1CALY<;N*<:.P0"`]PT%0#&ND-=Y)XVK(C&+24DQM17Q/89&!R7`R%&]\ M&'4S$S,[[LXHVF1S6Q%W%3=VBPQJ8S@9BFVRA1UW9Q1MLJ6MB+N*'K+9(V0H MMLF(N\"-9%HM_@E9$G>9F?_;Z#U@\T?`4.R`.76U,Y)VX`Y;5]+#AD=H:[>X M7XLH=MANE65JP$@L-J=,XJZDAVWY"!N*';:;K6$S$HO-*92X*[F96&5`X)!K M)PZWV3'N.A(O%?.*LS+B6M$?2AXE[\.#Y)6;';N\D MQ"W86O-Y["K/<2V95R.83J+)K7+L'.)&/1S.;.L6G+-7[/#8A%70AHLZR>MJ M^I*'V_5P/K.YM_DBMW))]P"(;LFIL]?5]/'!.!_@0[6]]B*W>HG16/ESR_<3 M31_?0V<%]FXNW\W85'"MN<\W^,`@#YT8E=K)G[-][&J-Q>?4=_R)YC9,NSX> M.CB@0>_DKU.\W7,AV9]4'GFAO(P=X-%P-(?9DZ:9-Q=:E%5/NQ<:FO#JYPG>U!BT M@N$(Q`E;S5'13T");>+]^_6^RU>;(- M@"/(T-F"-L[U.6-6-*"X370/'7ZIM%'!DNJ99-TO2:*2X[&AER M=OV5T*I'BJULI3L&4DJ4 MR!_K3AN^;3'O0S;CXL0=#F?T2@JCK:Y<@G0L&CW/^8[=,61:+DJ)&?BR$P-5 M05=9_C"G;+D(]?DI86]'[\0V>O_1R/*S[`"+C6WR#=AJ_>2ACZ4/X65V=GL3 M&O#5D!(JOFO=-[W_!+)N''9[C@GYO/+RN`8KL*!(DTR"#:%;-(!/HJ2?#"P( M/Q1T@L*R=$U!I]?)_":=9@@G6[!N(STE)6)GG5:_(B@+IB)7L+;FCB\71N\) MMAO1MN=^>+((L/@\BV3Z,Z3K#Q+07%.4=]B89^7639=L&>LAGC!/$0, M/O]@!@1#-X,EM#&V]'IY3LH>[)6Q\,'*0PR,92:ORTS_1\:#L=YC\^GUP!N5 M(V8VPLP'Q%\)(N3R!#T8FS-.*,MF`W&4CJ`+I'%0QM*^W;/TS1D\%=G?"AZ& M*K]$QHJW-X.IF&U&PO=V]R:W-H965TTD[;_?M=TPU@\I>T'X:L[*.@36'J[_/AA<=1F9QL`1Y"ALP5M MG.MSQJQH0'&;Z!XZ_%)IH[C#HZF9[0WP,EQ2+9NDZ9PI+CL:&7)S#H>N*BE@ MK<5>0>_'[)*+$W42I&/1Z.N<;]@-0Z;EHI28@2\[,5`5=)7E=S/* MEHM0GU\2CG;T3FRCCY^-++_*#K#8V";?@*W6.P^]+WT(+[-7MS>A`=\,*:'B M^]9]U\D1.RMT^IW!&7!5.0*UM;<\>7"Z"/!=B/:]MP/ M3Y8C\.$LBP=B*-T!)TAC8,RE@[M3M^=P5.1_:W@8:CR/TR MV[@(<=H4F!H^0=M:(O3>#_D$QV2(#ONWFOA.OHQ?YJNP$&SX@'O1\QH>N*EE M9TD+%5*FR17Z,G&SXL'I/LSX5COB4`@``U@8``!@```!X;"]W;W)K`"^'0ZIE:1POF.*RHX$A-Z=PZ*J2`FZTV"KH7"`QT'*' M_MM&]O:%38E3Z!0W#]O^3&C5(\5&MM(]#Z24*)'?U9TV?--BW$_)C(L7[F%S M1*^D,-KJRD5(QX*CQS%?LDN&3*ME*3$"GW9BH"KH.LFO+RA;+8?\_)"PLY-W M8AN]^VAD^5EV@,G&,OD";+1^\-"[TIOP,#LZ?3L4X(LA)51\V[JO>O<)9-TX MK/8<`_)QY>7S#5B!"46:*)U[)J%;=`!7HJ3O#$P(?QJ>.UFZIJ!I'"6S>(%H ML@'K;J5GI$1LK=/J9\`D>Z;`D>XY\+GG.%]$\RP^3_Y/PH(_0W@WW/'5TN@= MP99!2=MSWX!)CL2OQX.!>.S:@PN*+8V^6JS!XRJ;+]DCYDWL(=+D38(!\AL`OF=@8/X M$')Z?!Z,%9C&T>\M!PSTWM>PL::%"RCC* M,!(3!E/8.-VCWSA=M,.),KPV^/\`O#YQA.!*:_>R06$V_I%6OP```/__`P!0 M2P,$%``&``@````A`.INAX^&`@``?P8``!@```!X;"]W;W)K>E)*E,B>JE8;OF[0]SX9<7'D[A<7]$H*HZTN M781T+"1ZZ7G.Y@R9EHM"H@-?=F*@S.DJR>ZGE"T7?7U^2]C9D]_$UGKWV\K M*UX>P`HL*-)$Z=@S"=U@`O@D2OK.P(+P??_>R<+5.4V3*!G%$T23-5CW*#TC M)6)CG59_`B8Y,`6.],"![P/'[20:3^/;Y/\D+.33VWO@CB\71N\(M@Q*VH[[ M!DPR)'[;#QKQV)4'YQ1;&G.U>`;;Y72V8%NLFSA`[@,$GP,D&1`,-0=A%+M> MV(.]L"^LS^0^!$YETK=E;M\CX\$YQ>>0_'0RT`;A`!F=0,8#XLP?0J[WY\%X M`J=^+BH;,%=*(3+J!^^T-:;GM'[6 MTA&.[+^;T^\ZYP^1TXK-XE=&PL"'B5!@*O@$36.)T!L_S"GV^!`=[IE5ZC-^ M'1]EJ_[^8<,'G/^.5_"-FTJVEC10(F4<3;'`)MP@8>%TAWGC-:`=CG[_L\:+ M'K#/XPC!I=;NN$!A-OQU+/\"``#__P,`4$L#!!0`!@`(````(0"JT]=Q9P(` M`)<%```9````>&PO=V]R:W-H965TJXX\@;%2]R7-DI02Z(6N9-^4]/NWN[-+2JSC?<4[W4-)#V#I]>K]N^5. MFT?;`CB"#+TM:>O<4#!F10N*VT0/T..76AO%'1Y-P^Q@@%?ADNI8GJ;G3''9 MT\A0F%,X=%U+`;=:;!7T+I(8Z+A#_;:5@SVR*7$*G>+F<3N<":T&I-C(3KI# M(*5$B>*^Z;7AFP[KWF=S+H[ M=F*@+NDZ*VX6E*V6P9\?$G9V\DYLJW=^ZIWGT`VK<-N+[`@7U=1'6[!"C04:9(\R!"Z0P'X)$KZ MR4!#^+ZD.2:6E6M+.CM/%A?I+$,XV8!U=])34B*VUFGU,X*R("IR!6FWW/'5 MTN@=P78CV@[<#T]6(+'7-,/*(L.H\F\B49TG67N6DN*2HJI(^B$U#@HT]2^W?D<^_UO MD_VMH&%T^3DRS7CYXD>L-BY"G#8%IH$/T'66"+WU0Y[CF(S1_DG_%Y ML0X+P<8/N!<#;^"!FT;VEG10(V6:7*`N$SPHQOM,.-"*\M_@`!AS9- M$%QK[8X'O[OC+W7U"P``__\#`%!+`P04``8`"````"$`60/9]ZH#``!Z#0`` M&````'AL+W=O<$F: MFY)4Z5;=K;0KK59[>7;`2:P"1K;3M'^_,S:AV"2%O)`PC,_QF;$/9G'WFF?> M"Q62\6+I1X/0]VB1\)05NZ7_Y_?CS=3WI")%2C)>T*7_1J5_M_K\:7'DXEGN M*54>(!1RZ>^5*N=!(),]S8D<\)(6\&3+14X4W(I=($M!2:H'Y5D0A^$XR`DK M?(,P%WTP^';+$OK`DT-."V5`!,V(@OG+/2OE"2U/^L#E1#P?RIN$YR5`;%C& MU)L&];T\F3_M"B[()@/=K]&()"=L?=."SUDBN.1;-0"XP$RTK7D6S`)`6BU2 M!@JP[)Z@VZ6_CN;W\<@/5@M=H+^,'F7COR?W_/A5L/0[*RA4&_J$'=AP_HRI M3RF&8'#0&OVH._!3>"G=DD.F?O'C-\IV>P7MO@5%*&R>OCU0F4!%`680WR)2 MPC.8`%R]G.'2@(J05_U[9*G:+_UXXGL;*M4C0RC?2PY2\?R?>1A5$&9P7`V& MWVKP<#RXG83#"+@Z0`(S$:WK@2BR6@A^]&"Q`*4L"2Z]:`[`YX6``LQ=8_+2 MA\4,,P+@K(F!K#\Q)B,Q5A1GKA8L;(FF`-QDHW`V@(E]O#QQG,U@ M(LV:32^L$W3HWOL`DVTB$VE+F5T#B\DV;!6Q>C$\O]XB,+/^"G2VS56%VAIP M63:1M>F-.[NAASD4B`0AJR&C"WJN,HBH,@3CF-HBJM`9/;B'&[W6>L)N/6;K M@ZQZJT15R-)SP0]0M,L:CZ!I'Z]I/\.EJ?L-&PO=V]R:W-H965T&ULE%5;;YLP%'Z?M/^`_%X, MN38HI$I7=:NT2M.TR[-C#%C!&-E.T_[[G8,3!DVUT1X0^9&B"P_3B]'U; M@&\FR$3.#I7[KH]?A"Q*!]6>0T`85Y*]W`G+(:%`$T[FR,1U!0[`-5`2.P,2 MPI[;^U%FKDS)-`ZOY_/9XGH)-#MAW;U$3A+P@W5:_?:H^,3E628G%KB?61;A M?!E-8Q#]#PGU'K4!WC''-FNCCP$T#4C:AF$+Q@D0OQT1A(+8+8)3`DT-OEJH MPM,FCJ(U?8+4\1/FUF/@^A?3(2B(=LJ@-EX9P:B,N457;KVA+S-Y6V;Z'AD$ M0W%ZSB\7':T7]I!9#S+O$(/X`#(^/@1#"?KQ7*;6@T9(0SN,ET9P*]WE]F3I MIZ'OS"#*Q7ND$#R4\I99.WW]YE@.:?W`P=S^NS_QU)#?6_HIBZ/X[7KAKAX] M"0@>*GG+922K(>W(2/#4D/]D&8;RNN?]!O,#KH0IQ"=153;@^H#;:0(CVUF[ MQ;F=8/9?VV?)MEVHM/L`"ZUAA7ADII"U#2J1`V44X@(S?B7Z%Z<;\!P6DG:P MR=K'$OY<`J8V"@&<:^W.+R!,NW_AY@\```#__P,`4$L#!!0`!@`(````(0`Z M:1E?&PO=V]R:W-H965T&/ MXW/.=V-Q>U0U>01CI6XRFD0Q)=`(GWR MXX?%09N=K0`<08;&9K1RKDT9LZ("Q6VD6VCP2Z&-X@Z/IF2V-<#S[I*JV2B. M9TQQV=#`D)I+.'112`$;+?8*&A=(#-3V92XA$YQL]NW5T*K%BFV MLI;NU)%2HD1Z7S;:\&V->1^3"1=G[N[PAEY)8;35A8N0C@6C;W.^83<,F9:+ M7&(&ONS$0)'159*N9Y0M%UU]?DDXV,$[L94^?#8R_RH;P&)CFWP#MEKO//0^ M]R&\S-[2>@: M#>"3*.DG`PO"CQD=H;#,7971\2R:7L?C!.%D"];=24])B=A;I]7O`$HZ4X&K ML[;ACB\71A\(MAO1MN5^>)(4B<^>`D/O\F\FT9TG67F6C.*K\\9V4/]LJ^7-[*.@2&,J/W9<;_(^/! M6.^A^7C6\P;E@)D,,,\E>)$@0BY/T(.Q.<.$DOCZE70`72"-@W*YM`=WTGUQ M0V323=2P9;.7M-T4S7%!_MT[?^LE_U-DF$@2S_MD0Q7#@H4I5F!*^`1U;8G0 M>[\\(QR_/MKO]6KD/;^.3])5M^^L_X#[UO(2'K@I96-)#052QM$U)F["QH:# MTRTZQZW3#C>M>ZWPQPHX@7&$X$)K=SZ@,.M_U;5(U&\7QC"DN&QH84G,)ARX**>!.BYV"Q@42`S5WJ-]6LK5'-B4NH5/< M;'?ME="J18J-K*5[ZD@I42*]+QMM^*;&NA^3"1='[FYQ1J^D,-KJPD5(QX+0 M\YJOV35#IN4BEUB!MYT8*#*Z2M+;.67+1>?/3PD'.W@GMM*'3T;F7V0#:#:V MR3=@H_760^]S'\+-[&SWNFO`5T-R*/BN=M_TX3/(LG+8[2D6Y.M*\Z<[L`(- M19IH-/5,0M= M5K\"*.E$!:Y.VAUW?+DP^D"PW8BV+??#DZ1(?-04&'J5?Q.)ZCS)RK-D%.<4 M\ULT=K],XO&"[=$-\8RY#1A\_L'T"(9J>DDH8RCI=7N.F3W89_9V>2FW(3!, M,WH]S?A_TG@P^CT0/Y_UM"%Q@$P&D&F/.*D/(9?7Y\'8FV$]Y]8&T`6I<4Z& MJ7VWQSC';UOL-W42>H^?(T,[AJ).JIV=IGP[E0>?I@J123?#PR&9G]+Z2F;_ MK,1O.J4/D:%S23QYT;9PH,.I46!*^`AU;8G0.W]81SCN?;2_1U8CK_AE?)*N MNON%]1_P?+>\A`=N2ME84D.!E'$T1X=-N"'"PND6A>,IUPY/=O=:X44../%Q MA.!":W=<8&+6_QJ6OP$``/__`P!02P,$%``&``@````A`/;YELP;`P``E`D` M`!@```!X;"]W;W)K$H(!YK4I'QIDC([U_W5]?$4YHV&:U$PQ+RRA2Y67W^M-P)^:1* MQK0'#(U*2*EUN_!]E9:LIFHD6M;`+[F0-=7P*`M?M9+1S!RJ*S\*@IE?4]X0 MR["0EW"(/.DE=#653]OV*A5U"Q0;7G'] M:DB)5Z>+AZ(1DFXJ\/T23FBZYS8/`_J:IU(HD>L1T/DVT:'GV(]]8%HM,PX. ML.R>9'E"UN'B-IP2?[4T!?K#V4XYWSU5BMU7R;/OO&%0;>@3=F`CQ!-"'S(, MP6%_=."']#*6TVVE?XK=-\:+4D.[I^`(C2VRUSNF4J@HT(PBDT8J*D@` M/KV:XVA`1>A+0B(0YIDN$S*>C:;S8!P"W-LPI>\Y4A(OW2HMZK\6%)JD+)=) M[8YJNEI*L?.@WX!6+<7I"1=`O,_),G19OIBXS/@C,@B& M'Y^P\$/7A4$?:-D;XX@=?*.=CJ.= MV7DW]AX`4]W[$@ZOAOCZ'3=@V=4\/64AH@_Y=1UBRP_ADL;8[V>]^@9W8 MTH(]4EGP1GD5RX$S&.%K(^U6M0]:M)`Y;$:A81N:KR7\^V&PL`*\*W(A]/X! ME/WN_]3J'P```/__`P!02P,$%``&``@````A`*O7F74Q`0``0`(``!$`"`%D M;V-07B^CW+1ZR;Y!.=5:RI$LAPE8$0KE=E5Z'F]3*]1X@,W MDC>M@0KMP:,%N[PHA:6B=?#H6@LN*/!))!E/A:U0'8*E&'M1@^8^BPT3PVWK M-`_QZ';87Z%-00N>>#X`$SM1$0C4HH):3]<,P"DP-"`!A,\)AG! MW]T`3OL_+PS)65.KL+=QIE'WG"W%,9S:O5=3L>NZK)L/&M&?X,WJX6D8-57F ML"L!B!WVTW`?5G&56P7R=L_Z-]2WQJC??9!-2CP+^))P`;O'_^.?L"``#__P,` M4$L#!!0`!@`(````(0`*056_-`(````&```0``@!9&]C4')O<',O87!P+GAM M;""B!`$HH``!```````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````)Q434_; M0!"]5^I_L'P')X%&5;0Q@@`%J1]1X]#C:EF/DQ7VKK4S1(1?WUE;`:>-#^&V MGGEO_.937+Q49;0!C\;9:3P\'<016.UR8U?3>)G=GGR-(R1E,INRY["^4H1?_I5XHK":+AV^KD" M2\EH,!@G\$)@<\A/ZK>`<1MQLJ&/!LV=#OKP(=O6+#@5EW5=&JV(LTQ_&.T= MNH*BFQ<-I4BZ3L'J%J"?O:%M.A!)]U,LM"IAQH'30I4((GDWB#M0H6AS93RF M8D.3#6AR/D+SRF4;Q=&C0@ARIO%&>:,LL:P`:S^:=UDC^?2/\T^X!B`4"0-: M8_/L8KMO>#D@>CKN:&Q6MXE;0KHN2 M9T/>6.)ZR7O;=MNXKO*W'"XK\-P$*Z^,6X$%,EHNM.%Y`Y3W'Z`,/\`9'>3\ M=`1R*+,UR)FK:F6W_;"1_.:XTPQDX=[V`\_DE4*#TA5R[@%YY)L![">2Y!!$\K,R=\\:6]%##/3=J#1_(6]I2+(96CC5F9>652:3#]E'%*L#(4= MQ*9]_%?BC/HI/9G(Y?&4V?&4V^,I-\=3#@]@4^2^]._W!G!OU?Y9KN_&/N&R MSMPU]VIW/?:-8K%6'G+>JYW_W2#N^'#X,@29K95=0;[#_.\(M^ZA/>CI\/QT M<#;@,]:QB>3]=*=_`0``__\#`%!+`0(M`!0`!@`(````(0!`=`G4G0$``(\, M```3``````````````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT` M%``&``@````A`+55,"/U````3`(```L`````````````````U@,``%]R96QS M+RYR96QS4$L!`BT`%``&``@````A`.Z>.S1:`0``#@L``!H````````````` M````_`8``'AL+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`/MBI6V4!@``IQL``!,`````````````````=Q4``'AL+W1H96UE M+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`'#:R.F0)``#B2```#0`````` M```````````\'```>&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(R5"#3@`P``0`X``!@````````````` M````BT,``'AL+W=O&UL4$L!`BT`%``&``@````A`)3D15MB`@``EP4``!D````` M````````````/4H``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`.INAX^&`@``?P8` M`!@`````````````````H$\``'AL+W=O&UL4$L!`BT`%``&``@````A`%D#V?>J M`P``>@T``!@`````````````````^E0``'AL+W=O&PO=V]R:W-H965T``!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`/;YELP;`P``E`D``!@`````````````````'&$``'AL+W=O&UL4$L%!@`````9`!D`H08``#]J```````` ` end XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 5. Related Party Transactions
 9 Months Ended
Sep. 30, 2014
Notes  
Note 5. Related Party Transactions

Note 5. Related Party Transactions

An entity controlled by the Company's sole officer/director provided corporate securities compliance services to the Company valued at $4,000 during the three-month period ended September 30, 2014, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

Due Related Parties: Amounts due to related parties consist of advances made by our controlling shareholder for accounting fees and corporate regulatory compliance expenses provided by an entity controlled by the Company's sole officer/director. Such items due totaled $14,875 at September 30, 2014 and $0 at December 31, 2013.
EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]D,S`W9C0Y,E]D9#,T7S1C.31?.6(S85\R-6,R M9&-E,S1E-C$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?,U]"87-I#I7 M;W)K#I7;W)K5]4#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\ M>#I0#I%>&-E;%=O7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!);F9O M'0^4V5P(#,P+`T*"0DR,#$T/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO2!#96YT3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)S`P,#`X-38Y.#0\2!#;VUM;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)UEE2!6;VQU;G1A'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%SF5D.R!N;VYE(&ES3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,S`W9C0Y,E]D9#,T M7S1C.31?.6(S85\R-6,R9&-E,S1E-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9#,P-V8T.3)?9&0S-%\T8SDT7SEB,V%?,C5C,F1C93,T938Q M+U=O'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!R96QA=&5D('!A7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3PO8CX\+W`^(#QP/D%M97)I8V%N M($)I;V=E;F5T:6,@4V-I96YC97,L($EN8RX@*'1H92`F<75O=#M#;VUP86YY M)G%U;W0[+"`F(S$T-SM7928C,30X.R!O2!W87,@96YG86=E9"!I;B!T:&4@2!U;F1E2!# M;W5R="!%87-T97)N($1I2!E;65R9V5D(&9R;VT@0F%N:W)U<'1C M>2!#;W5R="X@3VX@075G=7-T(#$S+"`R,#$P+"!T:&4@0V]M<&%N>2=S('-O M;&4@;V9F:6-E2=S('-O;&4@ M97AE8W5T:79E(&]F9FEC97(O9&ER96-T;W(N(#PO<#X\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA2!I2=S(&%B:6QI='D@=&\@8V]N=&EN=64@87,@82!G;VEN9R!C;VYC M97)N+B!4:&5S92!F:6YA;F-I86P@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&EN(#!I;B`P<'0G M/CQB/DYO=&4@,RX@0F%S:7,@;V8@4')E2!F;W(@82!F86ER('-T871E;65N="!O9B!F:6YA;F-I86P@<&]S:71I M;VXL(')E2!297!O M2!O=&AE6QE/3-$)VUA M2!L:7%U:60@:6YV97-T;65N=',@=VET:"!O6QE/3-$)VUA&EM871E(&-A6EN9R!A;6]U M;G1S(&%P<')O>&EM871E(&9A:7(@=F%L=65S+CPO<#X@/'`@"!R971U2UF;W)W M87)D"!I"!L87=S(&EN8VQU9&EN9R!T87@@"!B96YE9FET M2!I;B!T87@@<&]S:71I;VYS+B!4:&ES(&=U:61A;F-E('!R97-C"!B96YE9FET('1O(&)E(')E8V]G;FEZ960N($9I2UT:&%N+6YO="(@=&\@8F4@F5D('5P;VX@=6QT:6UA=&4@&%M:6YA=&EO;B!B>2!5+E,N M(&9E9&5R86P@86YD('-T871E('1A>"!J=7)I2!A9&1I=&EO;F%L(&YE961E9"!L:6%B:6QI='D@9F]R('5N7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N M/CPO"TM/CQP('-T>6QE M/3-$)VUA2!B>2!T:&4@2=S('-O;&4@;V9F:6-E M2!B=70@2!N;W1E('1O('1H92!C;VYT2!B>2!I=',@9F]R;65R('-O;&4@;V9F:6-E M'!E;G-E(&)A;&%N8V4@=V%S("0Q+#@Y,RX\+W`^(#QP/DEN(&%C8V]R9&%N M8V4@06-C;W5N=&EN9R!3=&%N9&%R9"!#;V1I9FEC871I;VX@*")!4T,@(S@Q M-2(I+"`B/&D^06-C;W5N=&EN9R!F;W(@1&5R:79A=&EV92!);G-T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!42!V86QU M960@870@)#0L,#`P(&1U'!E;G-E2!C;VUP;&EA;F-E(&5X<&5N2!C;VYT3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]D,S`W9C0Y,E]D9#,T7S1C.31?.6(S85\R-6,R9&-E,S1E-C$-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#,P-V8T.3)?9&0S-%\T8SDT7SEB M,V%?,C5C,F1C93,T938Q+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SPA+2UE9W@M+3X\<#X\:3Y5'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS<&%N M/CPO"TM/CQP('-T>6QE/3-$;6%R9VEN M.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&D^0V%S:"!A;F0@0V%S:"!% M<75I=F%L96YT2!L:7%U:60@:6YV97-T;65N=',@=VET:"!O M3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D,S`W9C0Y,E]D9#,T7S1C M.31?.6(S85\R-6,R9&-E,S1E-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO9#,P-V8T.3)?9&0S-%\T8SDT7SEB,V%?,C5C,F1C93,T938Q+U=O M'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1&UA2!A7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO"TM/CQP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0^/&D^16%R;FEN9W,@<&5R($-O;6UO;B!3:&%R93H\+VD^($)A2!I9B!T:&]S92!O<'1I M;VYS(&%R92!E>&5R8VES86)L92!A;F0@870@<')I8V5S(&)E;&]W('1H92!A M=F5R86=E('-H87)E('!R:6-E(&9O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO&5S+"!0;VQI8WD\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!A8V-O=6YT&5S(&EN(&%C8V]R9&%N8V4@=VET:"!!4T,@(S&5S('!A>6%B;&4@;W(@"!R871E"!A2!A=F%I;&%B;&4@=&%X(&)E;F5F:71S(&YO="!E>'!E8W1E9"!T M;R!B92!R96%L:7IE9"X\+W`^(#QP/D%30R`W-#`@86QS;R!C;&%R:69I97,@ M=&AE(&%C8V]U;G1I;F<@9F]R('5N8V5R=&%I;G1Y(&EN('1A>"!P;W-I=&EO M;G,N(%1H:7,@9W5I9&%N8V4@<')E'1E&%M:6YA=&EO M;BX@268@=&AE('1A>"!P;W-I=&EO;B!IF5D('5P;VX@=6QT:6UA=&4@&%M:6YA=&EO;B!B>2!5+E,N(&9E9&5R M86P@86YD('-T871E('1A>"!J=7)I2!A9&1I M=&EO;F%L(&YE961E9"!L:6%B:6QI='D@9F]R('5N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!)3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SPA+2UE9W@M+3X\ M<"!S='EL93TS1&UA3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]D,S`W9C0Y,E]D9#,T7S1C.31?.6(S85\R-6,R M9&-E,S1E-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#,P-V8T M.3)?9&0S-%\T8SDT7SEB,V%?,C5C,F1C93,T938Q+U=O&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5]. M97AT4&%R=%]D,S`W9C0Y,E]D9#,T7S1C.31?.6(S85\R-6,R9&-E,S1E-C$M #+0T* ` end XML 14 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 4. Convertible Notes To Related Party
 9 Months Ended
Sep. 30, 2014
Notes  
Note 4. Convertible Notes To Related Party

Note 4. Convertible Notes to Related Party

On October 2, 2009, we issued a convertible promissory note in the amount of $76,000 to our sole officer/director. The note bears interest at the rate of 12% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.001 per share. The convertible note was issued in consideration of cash advances made and for services provided to the Company by the sole officer/director, who was also the Company's controlling shareholder. On August 13, 2010, the Company's sole officer/director transferred and assigned his controlling stock position to an unrelated third party but remained as the Company's sole executive officer/director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new controlling shareholder. A written agreement was entered into between the Company and the controlling shareholder on December 31, 2013 to assign the $76,000 convertible promissory note to the controlling shareholder.

As of September 30, 2014 and December 31, 2013, the outstanding note balance was $76,000 and accrued interest expense balance was $45,513 and $38,760, respectively.

On December 31, 2013, we issued a convertible promissory note in the amount of $255,681 to our controlling shareholder. The note bears interest at the rate of 1% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.25 per share. The note was issued in consideration of cash advances made and for services provided to the Company by its former sole officer/director and an entity controlled by our sole officer/director, who was also the Company's previous controlling shareholder.

As of September 30, 2014, the outstanding note balance was $255,681 and accrued interest expense balance was $1,893.

In accordance Accounting Standard Codification ("ASC #815"), "Accounting for Derivative Instruments and Hedging Activities", we evaluated the holder's non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments.

XML 15 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
American Biogenetic Sciences, Inc. - Balance Sheets (USD $)
Sep. 30, 2014
Dec. 31, 2013
Balance Sheets    
Total current assets $ 0 $ 0
Total Assets 0 0
Accounts payable - trade 7,625 2,250
Accrued interest expenses 47,406 38,760
Convertible note, related party 331,681 331,681
Advances from and accruals due to related party 14,875 0
Total current liabilities 401,587 372,691
Total liabilities 401,587 372,691
Preferred stock    [1]    [1]
Common stock 109 [2] 109 [2]
Additional paid in capital 46,191 46,191
Accumulated deficit (447,887) (418,991)
Total Stockholders' Deficit (401,587) (372,691)
Total Liabilities and Stockholders' Deficit $ 0 $ 0
[1] $0.0001 par value; 10,000,000 shares authorized; none issued
[2] $0.0001 par value; 100,000,000 shares authorized; 1,088,740 issued and outstanding at September 30, 2014 and December 31, 2013
XML 16 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 2. Going Concern
 9 Months Ended
Sep. 30, 2014
Notes  
Note 2. Going Concern

Note 2. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management's success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.
ZIP 17 0000856984-14-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000856984-14-000007-xbrl.zip M4$L#!!0````(`!=U;D4Z-!S M**GB`WQ)E"QG2Y:LK,J.I%CV9E-75ZDA,"0G!@$&#TG<7[_=/3/`@`3XEI5< M_"$Q16"Z>_K=/4W@].^/$Y_=BRB68?#JH-5P#I@(W-"3P>C5@8S#>K_?.ZZW M#O[^_7__U^G_U.OL-@J]U!4>&\S8FXL?SM['J4P$B\-A\L`C46-GWCT/\(;S M<#)-$Q&QJR`([WD"&.(:_.$V:G!M.HOD:)RP;\^_8VW'Z=?;3JO+_O?V]E\_ M]M^VCM^V.IWN=>_P[OK]N_]KL(>'AX;P1CPB;`TWG+!Z'4EZ'$0^@ST$\:N# M<9),3YI-O!>_;H31J`F@.TT9Q`G2=*#N/$GC^HCS:;9BR.,!W:TO-)&6NM.J M=UIF"0+T9+;"AG_85!?-K9Z8NR\6;F,4WC?A0@GDH?2SVR=\P'%S=)MSW'$R M]+X,/A5V^-`A_*WCX^,F7G2.1)3)#>BR$C1IPD MLZEX=1#+R=1'L/3=.!+#5P?(W[KA;>,Q]@Y8D^!HP9]<\R2-Q,WP9BHBI;', M#8-$/";O@E&(T6.]_LTH>8E_3\V'`7ZX#L$X6@WV M82S(('@PPVO-@;FK2?>S;.791$32Y0%[+<.1"$0B77;G2C!*H:V'?9L`L&_X M9/KR]S1,7AJPV1:)>^&'TXD($L8#CTW)[R`T M%@[90(;UZ9A'$^Z*%%C$?7-#W&`W!1*/:Q;J?,,,[`[P#H'L`0\^1>DT<64MI[#\&SX-XY"BB".`C,WD.X726JP7/E/F]7F5[#. M=_+W5'HRF0&+73^,X=X?0M"V\Q"L(PK(UC8V5]CWS!>O%-T3'HUD<.+(0'^L M#\(D"2+O!B!*F26'+C1R]`7==Q3%<-I0!.#7)40K`;=3Z MF(TY,&X@1`"Z+8#QQ.LXG>""@AU)WZ=]RR`5*`[.1D2,JX@I>!^`2M:=DC(` M$V/T*_AE($93QF0S]\B$EQZ+X09'\O`%>L(`]3E!JJNTT5:)8G MI@(,"HPMG8)&_<@#L'7<6Z8DJ0MNC=P#.@PQ!'-,%"9?3B2J'7@$,`"X"Q5R MFD("(.@ZW`N*!%L=I.!P$`BPDCUCW/L-;%A=3L8\81/* M@GB$U)'I)VB3*0)/P+Z26:/,4-:PA(+EO`:O'-\,ST#G4MS+:&]VPNB_:LOH MH*<$Y*@>M^C>@X1$M-I`+C.6WN4LG5.R$A,!`D$QKPJD, M='":9'JN7'3!TM.`IQZ!+U693%?`I"U=J:&\@(M$,*`(`]A,$$+\\\%"T)CQ M`B"*4N[#W8%`N^+1C`(<9T,NHQP-0LBQ&X]?0UM+?<7D/';7R-QR/Z!L7@9# MQ$Z10M.L@SB(^J<4HH2(@,3W`G*(!).&2[B=M9SZ3RP>AZD/]0-&>TZ+8&^_ M@<83,!(8^$C,M M,TBUPU)=S22;0+ZOXD0`P8%-P-F-8RWJ/#?L."3K+HD4:3>,E4"#A-#AZH`X MU"9.>(!H@]R@&Z:P6=(F^((L#GQ3"%^U8JWW&/B!XD?/L9$\!OP%1-DUPG=39>(<R&(D"MR4T/P:9@&I"IBTA@*@0(L(OCJ11<9Y4@G.B3 M2`I62D6V0,56OLHBXYY+GP^@GB-;SRR?DV07W>EB3FP1GL<'Y>%B*"EG!)S< M!F8P(K<[>YN@8+`G13/6HU"?3J'H?Z2M@_9$$64#^E[MFBO)@*+!Q3@A9L2C M7,/1^054AQHW(:,OO0V3<\@I@UBE$8:)`3[+B,@49;4S&E=B%< M)53!T:TQWL.HGJ>^*T@\-B[K06"5@7[N'D+8"()=2A(CGTH8:#7(,TVP/L+V MK^WRC*.[D#Y!+B"V(6R-7SE[7S4+P"5VX4D-;!*#39Y4NZ+!$]:0+)6VV M3K5`OJ7L6@ZU\S/WX_;$HXA<&>?ZBNY48G4Z$)`R<7KNFUC%J.743F)1YU&IT%+B7/+&'PM`X4%8_R4C)MHOO!I/A8:]S@GJ<^(]0!&<6"KI6H$/J."--;%*#9T#H+JUP>QB^J&G:W_ZL` M-B_8!_ZXF+N9^)SY3F2H5`L27%!6_5)4.^HZBU'-2C(1D(VY)'8]C*4[SB,8 ME)WA*)!&+4P,\HKT&.<.X$%AT\!3?P7677`!O*V5O%-O"D1."37JO;F0X]`M M)UQM&D%)`@49Z*F.4R`@;%]#!:P2,6J@ZU(6?'D=8#[PR(,(\Z/@&(=-8>P9 MN[(H!*^F@BCJ9,!=ZH?"]SY_,`&-U`HW@W&XEI>QD]70=2X[$*JTR([7K+@+ M=PV@.AIBEPP+%8R/BHI0%]*^_+)V**37A79W:>P&B*U1=AHKA) MF6"^EXQZTB2D'Q*I*-9M$QL]FV#G&^X5&&>YWGD1A2\_"5^.P]!3%0?`I\[H M`-M^<:*:U>1DQ2,VZB$A$(]\DK4,KX:+:*F)*3#=4/8P"2-1)T2S.B`)ZB`, M=47O)<-4L@=)3`](WI2C+>&2Q:&,/:8:+BO9=+LBYS+Z0P.#^HQ\5N2U)@=T M.!J!89FU=/-8-3I!K1(Z#N$!ZSE_LSE,)"I]5:JG.`OUC\J)0*,3GT@SKEW5 MV+F.%=4+_OH$K`&MM^N04/6%+2?10/=$GB&V2VM@$YZHZ$,)K-3I`,.2+X*F MQF/D;[O#6AXSY20=7#BV[WJ-;O']6T_QZ( MD=2\FL#/@$N90.G?)W0Q%4O2[+`]M%0U@*QT(Q$.Q M9Q0&(2J2U4(JWO)]T M$[`;-PE1!]MT7'D,&B0RB>HD5<$'>4S@0AC-J!=K_%3NC5X<'=8DBI%)O6#\B\J5U&GDDU=2+=U&FU_T9Y)P^@BF#(?)`5EYXYWB80=C&9`5*' MG4BV^C;,4KQA44?4"5"A*,`6EIV9J[P>]^8T'*>59\)J'S9[B"`Z5%?,4]TU M:K!D634U/[@:G<'VFB>RS"<6T3V5&,#F>VGEN\8):*=9RE4T^Y"04_@OW24= M__IDG;B!<>@#99_AQ%FA_+RGSE?$^T#,'3;HC>(F&52$P4AH*2&=-:LJLR1J M4EM4HW(>A"-!/6!"LZ"-F5``[$"UO0V3LCKNH5H\9^PADDF"^00$:A67U$0% MPM?Z/1#)`YZ.V>IBFI\5D-%A+IR&D%R(.EIJ['F9$]![J**_-%.MJJZ0Y`6: ME%CLZDPY#WWB@;PP=)9Z`]UC*B[H]FH]V"XN>-'IUXX.'3H6PVP;%,J?E:<& M-R4LV\5=MGN]VF&_9?QEI0ZLZS'_:`ZSW9OWEY_!1TI5+T]$10!2+,`"+\$D MS3!=U6*586NU@X5*Z5Z&Z1)/NXDMK*/U1GW65_M6K7^\V+Q0[0B[H6!U#.YT M)H>3491RD9CT";GJI+=Z^I2\QO)V@IP[WD+Q7>!9HSIKL_KG1/\_A#?"V\[0 M`.DXP4H<];C;0Z$N!/8HQAH!!&%0ASJ+@V-'\[-T4HV@DL[0W^HX"0\V")3' M)Y#QQU@TI[&@,WA=1FJ3Q=H-:N(0X`6F)VF<7U[9/8Q5&*#:35!K.6:_IU`W M#6@'S!:X*K[RHY;/GS?W&L44F=F$K9C;K'`<:V=, MF>?*!B_!J[GF"`V;L%!`TE&^\75S+HY.(*@E_:)+4<]JE-/Q6YV.WW3S=?XP MG`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`?YE\^C+Y]!>>?,ILHG3Z*;OZ M90+JRP34_X\)J#R@5@7)XD,CQ$,>4VX+LTEJV?-'V+_4:-:F\B@(\XQ"TKD. MQ)YPP9K]^-7!U?7E04%P;UK=GSH'H,52_?WQ[N+@>R>GH@!H6Q2[(-B=^(V! M;@I2)W6W*E7Z$'%/;,OYH\-VST)6#7D_%"S@;[=[SE;XL37R+F\*;[O_+B0Z MAP4"R@'O`_T"\D[_Z-#9%+DUH4@#BII7VS*@TVD=]EOV*<@R\'NC9)]TW."8 MP)SJG`7>(CLW9DZKVS^RS&-M1$]!WC(GL1UA^S`?I]7K']D/V%BJN[M;S%'[ M\+BU#;Y];FT[')MLIH#AUG22[K"1I'KMTGMUH*__6G+]5]K2K]([8(^Q/`GP M86D)Z,+J?<\]V6L[W&M@7H%7]54KD,Y?M':[L84[Q\438!ON3A2M0<\.U)QE M5<(ME]Y5<,ZG,L&G\VRJY8A^(WPM5(9MV';BW=)+2F,4%5$"N MW-Q_U:'(Z=M6OAK'7DDJ(:C5/[89LR%!I"YJ[";&X^$[$S&4/I0M"7OL,^_!--^U^URF'_D8?;*+%OYY=Z4'-FZ'E^';8ET:Z!I+] M$;24%5L09)V6WNGQQ5L]"O=Z9DV8K<@]UN/4!LCV3^!2SG7;CK,#D5>!&^'8 MUX50_UX%E:GRFVP4:&MNPM?MEB)V"\1/1_12#K>$KL-EU7(F*O,-D#Z-,16<'?>K^^9SBL:BH)E^9C_]CQ=368) MNB>A/T0,Y^M&D]`RU! M^224[J91JZBLF!6D&8IY=[H7^]P$X1-1NB9'-Z84U1CO?HW'35CQW`S5W>LG MTP63*(6U"Z;V]IC>!-YZ.(HUR@(6"\YV\#N;P<]K43TUO03X+RL*+`-C"\"= MIP&\MM7M@&%-:RG%\(,:W,>TJ_"3'YU];2R,7L$QKX"^/TI*I-?J'MFG/Y^) ME.7RQC/MYZ!IF89T#ZG^V8:F*_W[U6V5I7WL=.US_0*T[3&5*$.[W7?VCFFY MK/N'W<,G0+E,E(=49ZV#\CR,Z8=(ZU1WI:+K'QT5NLE%<#O@*K/D(Z?C/`&R M%;:J.E=/@'69"'5':RVLD%"J69A5;;12"=:+(BP`VQ9-B?#J<]+;`YX5U?N< MX/:"<)G(ZG,RJT8X/PI,<_P@73-8OXD(8\]``0J@V1])G>4DM3\[ M2=6:,4];YQEHJU*B>=IZV]'VLYY@/U,#[-?T(XN;(:V[R:?8=U`Z`A530Z]_ M9*O\=JB?G/K.GYCZ2E7^LVVC0NN?8AN>D"<7H4N_]OHPFRY_\1"^F.&T.;]D M`8ZJ5*%HO>`KWF2D7B-W7,=H5PDA@W\&ESR\?.GSY6]^&0)GA0)96)2!>D-/ M+,A?HW7-)\LI7?8^,_SMA4)6!G8.YSF0$N%O[#SQ^%8L__TI5!E.OW=XW._: MX.<@9/#UP,VEC%WN_R)XM(X$ZO56N]YI*?A5$.:WD)^,*96\L7]LMGX?94&? MUT,Q1\UM.O"E>^F'?-79_D_MA=2QV^ZV;;P6L#DTE](7T3DP8Z0>BE'-TCN@ M`.[5KT"1]#8MF@RV$17`S?-7B2%;C^\+29<_Q>`7$1?85PIA#LT_0S\-$AXI M6I;#OPYM\',KY^#^+'S_;1`^!'>"QV$@/#Q3%=$&\"L@+#B:7%$OX9OE.T!7 M4W0RI0*??[J5.)+Q_#'/A&C MET.*P@LES?LXSZ_>%EU%ODS!;%I`3Z=9&Q'^`).*$K)P\T)/3(KS;]5=0GL! MVUN+W#,`@ASH:5-O<6&[ROJ?8Y?J79M)@7[SW2;T/SOU'>.LMZ(>W-^ST^\< M;LG]7YY->^9MY.@);43EW\^^R\X:N^QLO\NY!/>/L-V5CF^'[>(1U3,;7GLW MQ_$'<'P;N6U,\HAX2O+H7OTKWN_URYU/X,IITWQ)`'!1<;7)3PL`U&_<5ZXM M="@(@"?Q#%OO#>^#,@UG2T+%B#5H_$ICFEM(P"Y$$-(O)!?!E5!L(,VO@A0F MH[)L5^IDLL"/*?ROBAOTRNIA&";X,,EW\$?AS=;X(UY\>)]YMW44^F+)&[/Q M,KW-6Q-`:_S0+<"$OW$S!J3/!\)?9S`?;BR^8OOK]8;YFWNF97-*=J6C8G:_ MFHPEP_Y[I6)#&A8I,(IW%A4IX9%[P/`QD-&K@U;#,2CP\1T;JDH2OCHP6'[M M=0_;%[WV>080\*Q0:7U'<\C=I&X`/?DF_E1;6*V>I3MH_Z%W\%ST%X@W;Z2> ML\AJ95C'/^?X'R<^@`Q&X.>#^L>[@^_I!0/XA@&N'TCUDK415/SJ& MI\DXC/"G]"_QH9'FR>.GS<(^]K6U]E-N;>G>6C6GWZ_A0STJGE94_>R`A<>= MEC!G[BL,O?#U:1.W!1_^`U!+`P04````"``7=6Y%CN.M.*(#``!5'0``%0`< M`&UA8F$M,C`Q-#`Y,S!?8V%L+GAM;%54"0`#OEIF5+Y:9E1U>`L``00E#@`` M!#D!``#=66%OVCP0_MQ)^P\>^Y!-:@@I[0:H;&)=]:H:ZQ!LTZ17KR9C'V#- ML7EMI\"_GQU(E[8)3;=6#?M":^D,=,P-(RXE98`7[ MJ$7A^]&IT/NS_5T>+Q:(.=(I5XJU.9(1\WX7$F?C1<1]C MK`%9,D)W:S-CYIT@<$;+L>)UJ::!]=$,4F#MZ9.]O03<66IVQ6#13.%A\.UC M?T1F$&&?"6T)M6+NK=54DL,0)LC]_3(\*R8=.$3`J/K>BT`Q@L4[)J<@P#`R(LS6,6A; M;N\P=QY&,P"C:RCATS&K.71KFD5S#NG>3,&D6W-N_-2%T^#Y'3T$OZ@0S$G, MDQ+IV_45W[`T("C0U+LC<\]<72";2+@D6>\>=Y4KE9>E[F4EG6`]3F2*M3_% M>)Y$$@`W.MU)DN0WPDVI/M]L?^\S/&:<&0:Z)^C(2/)C)CFU/>;T?WOWKE*? M'(^!=[W29L'CT.D1(F-A]`"O\)C#9X4IG,1*@3`%3+999$EDJJ.GKO+!BJ2' MVW^3TO`*[Z$-(M!Q%"6G^;9'1JG]1,GH#EE.PY#E^*!8V]#DW+G%W$-2V;,V M7R0+86H]W4;7L>\E5\71$5!_8L ML)'26V^R/.0NZI7+.%^D5D5$*CT@_"630?F1H+U-H4>F>TVJAYQ9*\WT'H>\ MZO+\XT>NK:-0=7G_WK=?5<:(TJ__;GGAMRN--0]5T&X:5:O'AWX74;D&^R`# M?.7:Z_T.1Y7KHO?^3)K?.H^#ZPS[=NU^@EQ?<"UAR;9SL%_OMWG3:,CE$"^<'[0HAS?<_Q.0"EF1071WZE>N2`H#)@8G1QQ+1TS\[J#=<_^O#^]:OS/US7Z2H9 M1!0"9S!WVA\_M7HZ8@8<+8=F2A0<.ZW@@0@;<"7#261`.1TAY`,QB*"/\896 MCO'99*[8:&R$6JD8<8 M-2\)/'S]ZN`@#F[.-'O685I+PGWOVY>;/AU#2%PFM+&C>NRH65/'[3>2QN-* M`>FLC;!W;A+FVB;7/W%K?F6F@R6B0\87,"$9$"N"9T6K-FK5I3B;:4L)5KH\ MB>`W&@TO?KHD"LPA?SE[W'A_^$LU>H+,0%LT\>'23**HDAQX,G:>_7WN= M53PFC!>PT'N*\0CGATY,MFGF$[@XU"R<<$C:Q@J&:WDDQ*WZ=:O[&YO-R\QI MC$04C0;@8BL(^Y+ER/%WV;-S7N1R`QB2B)L<&:_FSI6O#`G+4^"5U#FPC1.Y M(80#4'E2?99WB6="\E>&*R7$B_FQ0'W_*&F$`S?)M26"MC#,S#MB*%485[S- MU"V`FR2/.:;.O40?YPD3S+;>X.TS4)@9$`$$":SEG]OPLBG8"D$Q2L0EDR,0 M8!CM4X;K*FA<_BX)MQ6O/P8P>E<=MT`H5LW=B.2M:=\0`]9,?3>\PZKXN-LH M1-PU4'M4>3.C(N6^(GI\S>6T>+5_(OU/Q/XMH5T*+M.42QTIN)4&_/LQV+TS M$?.=J^S:A`67UC2XF04Z^23Q>'(ET1&U^T+T0LHR15J+G%FFVB71#&=I5X'& M^9IMV=ZF]W`12IJ);<,DL M;GTY\[TB0A.::;U.F[Y,05.QR"SE.ZRO(3/Q>H3[6#318#7!M8I!3FJ^B%"F MH&F)%%(WOVJX&[:U87@\`-V5G-%Y_)N;SENC[KO>IB57B!]VYV4G`5[:_T;L M@7`[+9>:NV$/*#;Q>4?K"((6I3**-RQ]0T1`5%">23L2VKN%&7B?QY^Y M%M\%L>4_4$L#!!0````(`!=U;D76CZ>PT@\``)"[```5`!P`;6%B82TR,#$T M,#DS,%]L86(N>&UL550)``.^6F94OEIF5'5X"P`!!"4.```$.0$``-5=;6_; M.!+^O`OL?^!U@S@<"EJB'5UERD?*><'A M_ON1E.3(DBA2(B6S0-$D,CDS'#XF.<.9T9M?'U8AN$.$!A%^>W!\>'0`$/8B M/\#+MP\L'\$5Q>O#^[H9L@1H!& MB_@>$O0'!W_!/XYF?SYVZL/QZ4_'\.O+$N#18 M`FD+_M<@:S;@CP;'+P8GQX@&+8#@^3I^ M7*.WSVBP6H?H6?KLEJ!%-;F0D"'O/\1H"6/D
_\PU^7WZ^!K.4?@, M\):?;D92R4YW:"6=AGW).$$DB/Q+W$[80N^>I9[&D,0&0/KMEO.T*CAQAA'_F9V)Q.S?=8L!$K!2><48Z\ M/,V#D"^7$3G(:^(@OXXL()T+FALZ6$*X%NO;$(4QS9Z(;6)P=)RNC]^GCS]_ M1#';6:(5NHXHS1B(D;T]J&XSS`O*&^Z(2A"--L1#!5+LQ^=:ED)-!PHU<5H' M?+-B9/D^B_#@T_3@%T80A(S6F^$3RZ*09\0#$?$123?KO,R0>-D#]JM"DK3% MT(O8ZKN.!YE0HON"1"N9WC*649TVAOM!P0BS\P:B\>7#&F%:G#Q9*V,D2-B: M8"$C"5!"TSE02,9K_4'WC%(4RU"9?F@,N%TFYGM90L\UP.R.LHB%*EWV-\T< MAF?8YS\N_[,)[F"(<$PG41AXCS-FU[]CO+](4*#7UQ@DC40T7H\@]H'X)$N[*4=) MY5;ZVC4$MU>5YI:J/=$ZV.97*8/L&D7@=1&$GR\B;[-BWQWV94H.GR.\B,A* M;-\2=&IW:XW%IH*9("_C(];.U);(L7(&=$UUDD&LW6SUZ+#:7;,5*Z*LM;GC MJEX,(^<5)^V@*:`8W M\8K84$P3C`O2PCKP$^*`666`5&2\S1K;B MJFKG8Z,;JBI&5BQ+3M`5A,@&FK^%DJNTOW5H>AN1>(;(Z@+-8Y4O5]+8>)6I M%\+XM/_3(3B/\!TB<3`/$>#/*)A%X`:%/(@-3"")G7/;UNNDN)+HS$Q_H+H( MJ,>.`AN"=/T-=3V,X:4ACBG&G#GU-!AS$4/:<]`?D/Y`/*2?[83LRPN7Z.-F M-4=DO!";Y7@3\TAOGEA0V#J1R#:5FJBD"V,8$]WBI&M&8 M]9JO<<`"\\C&^3G`MC. M-X2P,Z,$+?+VYF$8*E%,\),2!X'K4W]EF@A)KY@W"39=R7+&BL9%7 M4RV$T92GU!-/.$D-M'7"P!4$Z*DA[VS4G8S^-I;W"+-#4LBVN#-_%>"`G_/C MX`[5)[JH>AEO,IIBF4`L92&.*7"'B2OX:JB,XH[3:))Z]#3Q1(S;*&0ZI#R6 M+'Z4>9G*#/.V_PG5$_P8NT"+P@M@U0,FU4/(G*>9@+]DS#-%E MN12.)>WN-O-NM`0U`=[UZ.S=Z'HT&UU.P=G'"S"=C<\__'U\?7%Y,\T@>'DU M.A_-7(-@4RW5I/(TF,]N\WS2`_T-6D>$QUY,8QAOY.D^DN86LG[J!;&0_),R M`%L.(&'A"LIT55'.!=*9E#X7/09FGXGUY)-]'S&ISOG0">8>9^EZI^YI8:G3 M%L_X\N;%(1"T04K<%:BUT$5Y+6LX5WO/^!`%-4;8(PA2=(&2GS+'91,27>5_ MU`IL%+1UR_Y"(,#`8RQ=`V4;;6BF?FC,7WL/QQ4,B,C5'B^FB-P%S&1^B@M3 MNCR:]#;R@;00TP1KG!VXX_QXO"I-.8)URI*G1#KL*6FAK+SKI/6D]EDDA):*BC7$M&8BGUZ2!10ZM*< M[=:`K?"9^(G/Q+D8O^8V:E=6J14G2OW]81<7A]W<&*8WSJE!^G74)U%<%=J^ M(VR/E]RFF\;APW"$&89%O&*:_RN!D%Y?8U0U$M'X]/5[=OK:\@(Y9JZF?C?2 M41&-+>:QS^"9U2J(A2#<1A$E,98(\_2_BC`VF87:C(B%P)LV0AM[4'[FX:]; MSDGM@CQOUU#;3DWE")[VD]O>@,WBA28P8.;)B-(-O_<=+[@T$18'@PK#5:>7 MD<':0"PC+W'*AIFA@3!+@Y037SD]PE5_:]2C619'.9GM?5?%H(X13F\ADN*S-54*=7L:^;`:BF<"MQ\R M7C\"/^4F(GW2RR8H&#IS6&ZAG+PCJ]7D]7DIGM[.CQ?\^W#%ZV0IK\5KNEBX M&%<+9"_60JQ\@HP<7R+2%HXCT[@(YR'B.?.E/(V)6C3 M[V\,O<:BVDO%$]E2G`\,*?`W",313M"9_QKHJ8K7EO.YE9=Q>T$XB&M24 M%&[4U>9*J130S$L:BDNFZ2URL+!_$RW4K)>:\]1QILO3Y5;IED#JW:CM9"/K M14,H&[DOR?VEX/,<))S`V+U;HF:*J-UAJH='WNV\4Y5AV MVEAZ$TYG0930X1?CJ*JLR!7=IP/O_JD`]X1$F/WJH5RTG-X;#,:R>X M"?1&JS4[O/!%Z`9YC%/X"'@0#3,GGD3AV:78A\1WUK_<5G-E;Y_)G._=1UU1 MK+N9C[J*0(_EW*V="):B]D:<)&55%7)W#\!-==2^?OL>BZCEC?@9@3Y2EE&3 M]K!12$TECI'?)B4/U@E]=MJ+.0O7D*>AAHI::GK3TG?NWPP^Z.WMTN:6LO_D M@ACMU8(V8,3=O>E5C;\Z]T\U$_T!Z0;=(;R1[IO;CXV!4F1D`HR4EFM8*`ZQ M./?5RG2GII$$`\ING=*IM9\-56,[;@G7TB##AE5T"C&GG9_5JG\Q[M/!AO"!HOU*\>+SP6<5_^&F+GSC#R@9>,+H7:;48!2>]`)97+VU*Q'!VD+;;AR3@) M#_HA"Q3ZD4<*P:(-MKT^1^[51C=47WTL4<-I[]$IX/][0Y/\T%ET@[A^@A!] M1'%B&/!W@\TB.Z^7[H25N1NB0P68Q9ULY4J"3%+)MJE/_*F7#PC]*EYBW:6Z M2WZ2S@'7<9@!DYSP:@,^>OB`Y$DTQ78V@@FJ6=N('T@H`T$:,-JN(%0Y^(H8 M@3K%FX4%O&/G7\QS`A7!`>5VQB$"4M86`@7F&>UNP@6,1$_$F<:0Q(JP@8:C MV$?P@%03Q1`"!8#V?J=6$>G?[I7)=81ZS`/I\I7)52DASIT`VJNJ?6[(OH.K MRR6M].NU%SMT4(C,*B;3*)H<%^<@J-:`NB;9OB%5+!F@=_&FZF6]&D0'UW`9 M"S#A&=EI."KGY>J=G*9.5$4AG+FAVQ:;?9P1B"G?:R+"NBOHT5!`WCVL-0'=7A[\@<+P`X[N\11!&F'DB[0"4H&6^O86+A,4HEBX M5.`SLJ"4\G:RG*3 M4`:,-."T7<)*[>"KEIH:Q?>=#*B*`[!4#:>>J9$I-9U>SJ:NP*%^G-4I@/OV M3MZ@&`9LJ0^E&'`O3>%:I;TC9T8)+2%P*``"^FP``%0`<`&UA8F$M,C`Q-#`Y,S!?<')E+GAM M;%54"0`#OEIF5+Y:9E1U>`L``00E#@``!#D!``#M76U3XS@2_CQ;M?\A-_N! MNZH)(3#,`37<%@282@T+*6!V]^KJ:DJQ.XEV'"DGR8'\^Y/LO#J6+3N);5%\ MX<5I2=W/HVY+K9=\_O5EZ-7&P#BFY'RON7^P5P/B4!>3_OD>YK1^WZZLO%`_>Q@!JG/?&,&'RH7;AC1)1`BPY' MO@!6:Q-"QTC(%O@'^8^S_T%^-IHPW!^(VM];_Z@='AR9C\.%,_NHA# M31I#^/G[@1"CLT9#%7KI,F^?LGY#MG'4F`F^__FG=^\"X;,7CE<*/!_-Q)N- M/W^[?70&,$1U3+A05H4%.3[CP?-;Z@1V&319TTJH_^HSL;IZ5&\>UH^:^R_< M75*TA[UY,T/410J$A@+MX/3H8$E.U901@K4B4Q":IZ>GC>#396E9G2OFXLNU M'S?"#R/2.$&=.;"2S'I0-`X[>UP)+SL1D!.?O.1Z./)@]&S#HG;]7#=1GE2OT?S&NN[%0 M?\2`2['@^:U\L-(LO`@@+KBSAI4%6S-0Z3!5PJ/.*@+WOF><;%&5A67.QD'9[]/QPT7<("0^B-0OW[0G+K+ M+_+1][#Y!^ACU2H1=V@($86U8LL*+A-YP5:51A(%43>7HTR%U@8VPO!?V;(DZPV!O>5 MCRW#>]6T>)P/B\:Y`PQ3:8-[A402X*MREB(?,3:>@J.B*+B0*KE*K1L/]6.@ M7_W<,L@CQL5#_;$HJ$.U6U(=AKRV?(>^?(6)-JQ'Y2R#7F-L/`7'15'0\IDR M]`9S!WG_!L3T,4I/CN?A4L#O0X9"21T&='X\#:3R_]X4:3ZOIF]XW MD@I9QH\)#/%,_;-8ICI^U\/.C4=1=/`<+V,E#RM&QL-^4BSL-]@#UI(.VZ=, M_[98E;(2^HBA\>"?%AR=PN#Y`"/*A'3%1XFCS_5Q*5[<2CITIFNF9@?%$O,[ M]7R)(@M[C9Z1J)R55*P9J^&@L/EQJ-8?X'E?"7TFCX`X)>"V.?>!:;G0R5O) MB=9X#3>%SZD7`[X;^23.0W22EO&A-5C#1&%3ZU7%PFF_&1?+LE:SL6*TAH_Y M_/MS8\W(6_E@H[3ZQ5!JX"!RB6D?"`CL/#H8B`.\39Q+Y*G$_>,`0/"\R?4, M+>PZQ9Y!E4WZ?P_Q;M"5?%[O(S0*G0`\P6=/HMXP??Q=C2%`]8[[W@TF4ATL MNPCE."$QGZGH1FZ=WZP+SB6F*09$A$IRZSQ,*-?6F;JC1/VF7$P'KXE4S&2L M9F)NZ(XR^9L2DK#QM1QGQPU[N9GC"-O+UTZ0#8T0)$?K):E(R!"2R[U1T5 M,.MBR8RE%+*4MC0H=K2*D9^[>S$`%HD-\GV\WOTT-)J7MY31#`#M:)5DFP,5 MXP&*K729!\S-5TFV0DPZ(Z^`BMVMDFR2_\HX(WM]<[#LLZ[-ET[R$]:1=8%T MZ7"R^#OR_.A6H21)2RF*-7I7BRF;#`'G6V:2B%D3LY25=7/3UE-*F$*Y+@[5 MZ2#LMDD+C;!0NL5/H#32EA*D-5[#4XG9B0<0"!-PKQ$CF/2Y'%GZ0]^3=KM7 MT,,.UKV/#`I:RIX))!HB2\Q9K+]-C0<2MA(59[*&F!+S$VFIYIP9>%M)2X=# M0^%):9L#YJ;R^][]"%AX^G,GNP0T396Z74"C4SG>)/6A0YBKE#)ITDF7]K(= M`_&UL^[YQR6[=@K&J^_*F4656_YO42Y4B+E^&0'AD+8I0RMN#QEZBRNW)>"+ MC#(,>2J5Z0XQ"4Y\"CR&J>H:CM)*V4-5JOV5VU#0)@(DI"*9H:B4/8RLV5>Y MA?^H>QL&,HLX6+>P. M["Y7V//EY#SE!6]:VAZ^C/&HW)I]BN;Y&'P]S%5PI?X/4!<HQV$)Z&5MB&@U/Q6"_'! MC4>?=Y_>6K14F>S60J72#\7,53$_#+->I+PQLM*EP^@82[HN)]\XN&TRS1W* M".C(J6Z8`4XV+D=%UQF!V964M;1$TF4+:8"(RG2/HR`\3A"L+?;3([ M6I1TI#=+28NH,09CBSE"4UJTN^$U>?&\M5A-EP%(E4L*:L;"+4KD*]27;]'% MYH-L\X78&BRA-Q:K1ODS'P;+1 M(8WVTQV`FSMR4D6O@^A$J+9Y3BE^/#7]0@M^(VU+G7@D"%M"1IK)U3MG9-YM M-O8L6TC,`TT%#RE)U>4X7/U2.YW'R%,)I?!:M.@`7K>U)TL5EI&;#9YM'GB* M#Y1*D4OH8Z(6ZN][H2(Q,3)>SA+P$PQ-.*J4,5\^"FJ4*C&1,VNN9^B:N"G< M+$M8QLJ*<0DGCG+Q(2M?8F,7:\Y7F#L>Y3X++J-H/@U`?8D6(I/<7UZDK7#G MWUBD;;F<=\E"GR=ITJ5LZ4?*>#NI1%DC'22D.LMG2G0CFG7!DCW9`/^5@4N, MI2FKN+MWR,,O5`;\%I5#8Y;_^\02JBS6*5?;?G/+#UR7",L2O?D([7%C,NAPE(3VW'HV)J+]>M8%=[<.[<14SBG"T3K7ZVC ME[/+=6/L+-U1/T8O:%/;2>8)J2V-B],:*=9]T[1Y\^3\NT4'E(DG8,,KZ(JY M5KI]HO'"=OFTSN+2'?MXN4\_,42XM&"32P),JR_6F?5ZO+GQ!I<"Q&,:HZK& MJ"PUV.7PF;`I/0I\4IL*<;A15*6R@[T9?2`.ABT%@L06BHT%B:J\A8.-[K+3 MP&H>$3)68E=0R(I0Z7$A;@K[C<-][YH+/$3JHF;J86<2_-Q:K,C<:OGS^D3U M2KKV,U#"-)[HI$N*):MX:G2.")4<"U+P7HX#4>LJZ>>:9>V"_-VH]?+]WDC- M-__?UI:3526S[36)E+4G6AAB4OG1Q$C-MR"26?GH M74AFPY.T4O8$CE3[*QDRPJ/O3^BEN.2%OLGR@X->M[>(D%GY.9AFH4`K;D\, MT%M<3>"J>$F`L``00E#@``!#D!``#M6EMOVS84?NZ`_0BDMLG)T=MV[7>O?W]M\X?MHT&@ON)1WPT MG*+>Y?NS.YE019#D@7K$@NRC,W^"F2:XX%&<*")0GS$^P0HTR'UH>(U]&(NG M@H[&"KV^>(,.FLT3^Z#I'J*_!X//'T\^N.T/;JMU>'-T?']S=_U/`ST^/C:( M/\+":&MX/$*VK2%);TPBC,`*)KO66*GXU'$T]6.KP<7(`=&N\_GC];VALU+" MTT3:(XSC&4.`Y="09P..!F,W7;OEYBQ/0Q'Z:L:AF[F"(R<=G)&&E'U=!\9M MM]N.&<4%B.B;G!$9(P] M4D6:REL!6C2KY>CA(9;$0E@I08?@S2LNHDL2X"2$N4C8MP2'-*#$A[`)2428 M6B`H#,]GD59HI$PJ'3T6^/95!T/@*!,XN@GM.*8LX*;QJJ/1G>80[TB`S,R> MJFE,NGN21G%(]K*^L2!!=T]/@YU/P9=8D`:`RDD$#X&M%)@>=H!%@HD&T?5< M<2X""V]%RHKG00B/B5"4R-G\[CD_QR2?!)N:!"R4T5_5H!`/-S4(6$CX*]KB MX7!36X#%2\)_.=RTC`>P`>F'3W?]F;R5JI&"HK[X/T+=-*.;-)K+17!8TM#ATW$`% MB0@SO?X49':<96%%'8DD_BU[:YZ7DSSCS$C*N!;SJ![/DGO7,&5=N8M^KML. MWG.8'I@ECPA6YJ=%H@K'-(_7.^:@@8P(E,G8.6)ECEOG6%)Y&PP*!E]@.=9Y M`7^];PF=X%#']8"'U)N:WXK<>K:\JKP[6._>5@,9;8@'J*CO%&E5:1[JAX+2 M?92J1:]SQ6]V05'+B3TL&*22'!"ABQUG]V/8(0"5* M=2*C=!<4SPV*31Q>6<#_W,R9._?4FO(K3,5?.$S(;7!%&9QM*`[[<,H12;1= M1=],<%46MS;-8JT:&=UZ;*8=%=3O\KE.P+@/8Z)?DV`V+7-]D:0J>X_6.]%M M(!"`,@D[%\#\GD5$4`^S<\KA<$`4]>XA/F%S*OO,NP>3S7L,R#:]<;D*^6,A M+9_!6^4TLW[.V.`YEX_F"E"NP;PZ*]*;S#2[*Z-IY]Q:=;,/F>"IV^".>-`5 M3OM2)L0_\SR>F/,B3"_SL?"W*,W/55%5I$N.5^5%.@6A^W,8*,6!YD#0#,FN M7M>)IT,XQ$[TVY1A:-KR@=\1@$/\`1:JM(;_B*VJ1)RL]_NA?M\Q$VKZ)'K@ M*).+C."=![4KN&>V)/D_G()[$/QJVF)&GRET'FZS`^_D2G,E'J8*=#UH\EY[?7$\:BS60504N/-6K3W,)PD'RYY4%.H4V6(O5"FG M:L/C;KKA`4VZURS3TS4G&/ M0K?L_#*%K;ML]\!NN8TGZ5N(K=P0J;B)X6P*P%?"T1_%'9:87-;JVUJ]>UQ+ M_3+_-@@XN]D6!&?VLX$4+@=I`$=EJM?>)EK0MLI3>6>I!)S1LY;1(:&2>8\] M%Y4B_@&4RIM+55"6>?1#B?+L>A'"0ZD$;.6ZEA()@UIO"EYIZ("86=S$#P"?4)("Z<>V!!RZW: MB.672A!8L`7!DER2]+_/+A(A=!9("6?EY1RI3?ZR+ER%F;U$A;B;:B"0X]`# M6/P\(,LMK,'ZLM9F5WCEE>#1^OBLHO@OL:>[%#6'KC^'G),19?J:`>Q8#6V. MNF3PQ0'WF+\.ZD*W!MEQTL44'K\#4$L!`AX#%`````@`%W5N13HT'-R.&``` M+X4``!$`&````````0```*2!`````&UA8F$M,C`Q-#`Y,S`N>&UL550%``.^ M6F94=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`%W5N18[CK3BB`P``51T` M`!4`&````````0```*2!V1@``&UA8F$M,C`Q-#`Y,S!?8V%L+GAM;%54!0`# MOEIF5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!=U;D7PC]EFS`,``.D< M```5`!@```````$```"D@`L``00E#@``!#D!``!02P$"'@,4````"``7=6Y%UH^GL-(/``"0 MNP``%0`8```````!````I('E(```;6%B82TR,#$T,#DS,%]L86(N>&UL550% M``.^6F94=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`%W5N1=-CB=7L"@`` MOIL``!4`&````````0```*2!!C$``&UA8F$M,C`Q-#`Y,S!?<')E+GAM;%54 M!0`#OEIF5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!=U;D4*&;<;@@8` M`+DM```1`!@```````$```"D@4$\``!M86)A+3(P,30P.3,P+GAS9%54!0`# IOEIF5'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```.0P`````` ` end XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation
 9 Months Ended
Sep. 30, 2014
Notes  
Note 3. Basis of Presentation

Note 3. Basis of Presentation

The Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013. The accounting policies are described in the “Notes to the Financial Statements” in the 2013 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.

Fair Value of Financial Instruments: ASC #825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.

Earnings per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of September 30, 2014 or 2013.

Income Taxes: The Company accounts for income taxes in accordance with ASC #740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed "more-likely-than-not" to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions.

Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at September 30, 2014 and 2013. The Company has net operating losses of about $447,887, which begin to expire in 2025.

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
American Biogenetic Sciences Inc. - Statements of Operations (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Statements of Operations        
Revenue $ 0 $ 0 $ 0 $ 0
General and administrative 5,875 14,750 20,250 46,000
Interest expenses 2,904 2,280 8,646 6,840
Total costs and expenses 8,779 17,030 28,896 52,840
Net loss $ (8,779) $ (17,030) $ (28,896) $ (52,840)
Basic and diluted net loss $ (0.01) $ (0.02) $ (0.03) $ (0.05)
Basic and diluted 1,088,740 1,088,740 1,088,740 1,088,740
XML 21 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information (USD $)
 9 Months Ended
Sep. 30, 2014
Jun. 30, 2013
Document and Entity Information:    
Entity Registrant Name American Biogenetic Sciences Inc  
Document Type 10-Q  
Document Period End Date Sep. 30, 2014  
Amendment Flag false  
Entity Central Index Key 0000856984  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding 1,088,740  
Entity Public Float   $ 54,242
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q3  
XML 22 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
American Biogenetic Sciences Inc. - Statements of Cash Flows (USD $)
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Statements of Cash Flows    
Net loss (28,896) (52,840)
Expenses paid by issuance of common stock 0 0
Fair value of services provided by related parties 0 42,000
Increase (decrease) in accounts payable and accrued expenses 14,021 10,840
Cash flows used by operating activities $ (14,875) $ 0
Cash used in investing activities 0 0
Advances from related parties 14,875 0
Cash generated by financing activities 14,875 0
Change in cash $ 0 $ 0
Cash - beginning of period 0 0
Cash - end of period 0 0
XML 23 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies)
 9 Months Ended
Sep. 30, 2014
Policies  
Cash and Cash Equivalents, Policy

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.
XML 24 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation: Use of Estimates, Policy (Policies)
 9 Months Ended
Sep. 30, 2014
Policies  
Use of Estimates, Policy

Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
XML 25 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation: Income Taxes, Policy (Policies)
 9 Months Ended
Sep. 30, 2014
Policies  
Income Taxes, Policy

Income Taxes: The Company accounts for income taxes in accordance with ASC #740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed "more-likely-than-not" to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions.

Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at September 30, 2014 and 2013. The Company has net operating losses of about $447,887, which begin to expire in 2025.
XML 26 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies)
 9 Months Ended
Sep. 30, 2014
Policies  
Fair Value of Financial Instruments, Policy

Fair Value of Financial Instruments: ASC #825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.
XML 27 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies)
 9 Months Ended
Sep. 30, 2014
Policies  
Earnings Per Common Share, Policy

Earnings per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of September 30, 2014 or 2013.
XML 28 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards, Policy (Policies)
 9 Months Ended
Sep. 30, 2014
Policies  
Impact of Recently Issued Accounting Standards, Policy

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

XML 29 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 1. The Company
 9 Months Ended
Sep. 30, 2014
Notes  
Note 1. The Company

Note 1. The Company

American Biogenetic Sciences, Inc. (the "Company", “We” or the "Registrant") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court. On August 13, 2010, the Company's sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company's sole executive officer/director.

XML 30 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 6. Commitments and Contingencies
 9 Months Ended
Sep. 30, 2014
Notes  
Note 6. Commitments and Contingencies

Note 6. Commitments and Contingencies

There are no pending or threatened legal proceedings as of September 30, 2014. The Company has no non-cancellable operating leases.
XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 9 58 1 true 0 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://maba.com/20140930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets Sheet http://maba.com/20140930/role/idr_AmericanBiogeneticSciencesIncBalanceSheets American Biogenetic Sciences, Inc. - Balance Sheets false false R3.htm 000030 - Statement - American Biogenetic Sciences Inc. - Statements of Operations Sheet http://maba.com/20140930/role/idr_AmericanBiogeneticSciencesIncStatementsOfOperations American Biogenetic Sciences Inc. - Statements of Operations false false R4.htm 000040 - Statement - American Biogenetic Sciences Inc. - Statements of Cash Flows Sheet http://maba.com/20140930/role/idr_AmericanBiogeneticSciencesIncStatementsOfCashFlows American Biogenetic Sciences Inc. - Statements of Cash Flows false false R5.htm 000050 - Disclosure - Note 1. The Company Sheet http://maba.com/20140930/role/idr_DisclosureNote1TheCompany Note 1. The Company false false R6.htm 000060 - Disclosure - Note 2. Going Concern Sheet http://maba.com/20140930/role/idr_DisclosureNote2GoingConcern Note 2. Going Concern false false R7.htm 000070 - Disclosure - Note 3. Basis of Presentation Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentation Note 3. Basis of Presentation false false R8.htm 000080 - Disclosure - Note 4. Convertible Notes To Related Party Notes http://maba.com/20140930/role/idr_DisclosureNote4ConvertibleNotesToRelatedParty Note 4. Convertible Notes To Related Party false false R9.htm 000090 - Disclosure - Note 5. Related Party Transactions Sheet http://maba.com/20140930/role/idr_DisclosureNote5RelatedPartyTransactions Note 5. Related Party Transactions false false R10.htm 000100 - Disclosure - Note 6. Commitments and Contingencies Sheet http://maba.com/20140930/role/idr_DisclosureNote6CommitmentsAndContingencies Note 6. Commitments and Contingencies false false R11.htm 000110 - Disclosure - Note 3. Basis of Presentation: Use of Estimates, Policy (Policies) Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentationUseOfEstimatesPolicyPolicies Note 3. Basis of Presentation: Use of Estimates, Policy (Policies) false false R12.htm 000120 - Disclosure - Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies) Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentationCashAndCashEquivalentsPolicyPolicies Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies) false false R13.htm 000130 - Disclosure - Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies) Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentationFairValueOfFinancialInstrumentsPolicyPolicies Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies) false false R14.htm 000140 - Disclosure - Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies) Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentationEarningsPerCommonSharePolicyPolicies Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies) false false R15.htm 000150 - Disclosure - Note 3. Basis of Presentation: Income Taxes, Policy (Policies) Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentationIncomeTaxesPolicyPolicies Note 3. Basis of Presentation: Income Taxes, Policy (Policies) false false R16.htm 000160 - Disclosure - Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards, Policy (Policies) Sheet http://maba.com/20140930/role/idr_DisclosureNote3BasisOfPresentationImpactOfRecentlyIssuedAccountingStandardsPolicyPolicies Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards, Policy (Policies) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets Process Flow-Through: 000030 - Statement - American Biogenetic Sciences Inc. - Statements of Operations Process Flow-Through: 000040 - Statement - American Biogenetic Sciences Inc. - Statements of Cash Flows maba-20140930.xml maba-20140930.xsd maba-20140930_cal.xml maba-20140930_def.xml maba-20140930_lab.xml maba-20140930_pre.xml true true